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Summary 
The mitogen-activated protein kinase p38 plays a crucial role in the onset of 
inflammation. Due to their potent anti-inflammatory effects, p38-inhibitors have been 
evaluated in clinical studies for the treatment of inflammatory diseases, such as 
rheumatoid arthritis or Crohn’s disease. However, most clinical trials failed to show 
clinical efficacy, and moreover, there was an unexpected appearance of inflammatory 
events under p38-inhibitor treatment in some patients. However, the underlying 
mechanism how inhibition of p38 may promote inflammation is largely unknown. I now 
show that the p38 inhibitors BIRB0796 and SB203580 augment the expression of the 
proinflammatory cytokine IL-12 in human monocytes or murine macrophages after 
stimulation with Toll-like receptor (TLR) ligands, while the production of the anti-
inflammatory cytokine IL-10 is abrogated. On the molecular level, inhibition of p38 
blocked the TLR-induced activation of the serine/threonine kinase mTOR, a recently 
identified critical regulator of IL-12/IL-10 production in the innate immune system. In 
agreement, direct inhibition of mTOR increased IL-12 production, while IL-10 was 
profoundly blocked. Activation of p38 with anisomycin or UV induced mTOR signaling, 
and accordingly, blocked IL-12 but enhanced IL-10 production of LPS-stimulated 
monocytes. Moreover, p38-mediated activation of mTOR in monocytes was dependent 
on TSC2, as deletion of TSC2 abolished the inhibitory effects of BIRB0796 and 
SB203580 on mTOR. Additionally, I observed that the isoform p38α is responsible for 
the activation of mTOR, as deletion of p38α in mouse macrophages blocked mTOR 
activation after TLR stimulation. In vivo, macrophage-specific knockout of p38α blocked 
mTOR signaling in the spleen of mice challenged with LPS and raised the IL-12 serum 
levels, while the levels of IL-10 were attenuated. On the functional level, inhibition of 
p38 or mTOR in monocytes strongly promoted the differentiation of CD4+ Th1 cells. In 
conclusion, we provide evidence that inhibition of p38 has proinflammatory effects in 
human monocytes as well as mouse macrophages and identify a novel link from p38 to 
mTOR that is central for the regulation of the innate immune response. 
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Zusammenfassung 
Die Mitogen-aktivierte Proteinkinase p38 spielt eine entscheidende Rolle bei der 
Entstehung einer Entzündungsreaktion. Inhibitoren von p38 wurden aufgrund ihrer 
entzündungshemmenden Eigenschaften in klinischen Studien eingesetzt, um ihre 
Wirkung in Krankheiten, wie zum Beispiel Arthritis oder Morbus Crohn, zu untersuchen. 
Viele dieser klinischen Studien zeigten jedoch keine Wirksamkeit der Inhibitoren und 
darüber hinaus konnte sogar das Auftreten von Entzündungen beobachtet werden. Der 
grundlegende Mechanismus, der dazu führt, dass durch die Inhibierung von p38 
Entzündungen auftreten können, ist bislang unbekannt. Wir zeigen hier, dass die 
Hemmung von p38 durch die Inhibitoren BIRB0796 und SB203580 in humanen 
Monozyten dazu führt, dass nach Stimulierung von Toll-like Rezeptoren (TLR) die 
Produktion des entzündungsfördernden IL-12 gesteigert wird, während die Expression 
des entzündungshemmenden IL-10 vermindert wird. Auf der molekularen Ebene kann 
man durch Hemmung von p38 die Aktivierung der Serin/Threonin Kinase mammalian 
target of rapamycin (mTOR) verhindern, deren Funktion als wichtiger Regulator der  
IL-12/IL-10 Produktion in der angeborenen Immunität erst vor kurzem entdeckt wurde. 
Direkte Inhibierung von mTOR durch Rapamycin steigert ebenfalls die Produktion von 
IL-12 und senkt die Expression von IL-10. Gleichzeitige Aktivierung von p38 und 
mTOR in Monozyten durch UV Licht und LPS senkt die Freisetzung von IL-12, 
während IL-10 vermehrt exprimiert wird. Darüber hinaus konnten wir zeigen, dass die 
Aktivierung von mTOR durch p38 über TSC2 verläuft, da in Zellen, bei denen TSC2 
deletiert ist, die p38 Inhibitoren BIRB0796 und SB203580 ihre inhibierende Wirkung auf 
mTOR nicht mehr ausüben konnten. Darüber hinaus konnten wir durch die 
Verwendung von Knockout-Mausmakrophagen feststellen, dass die Untereinheit p38α 
für die Aktivierung von mTOR verantwortlich ist. Durch die Inhibierung von p38 oder 
mTOR in humanen Monozyten differenzierten CD4+Helferzellen, die zusammen mit 
den Monozyten inkubiert wurden, verstärkt zu Th1 Zellen. In vivo Experimente zeigten, 
dass der Makrophagen-spezifische Knockout von p38 den Gehalt von IL-12 im Serum 
von Mäusen steigerte, nachdem sie mit LPS infiziert wurden, während der Gehalt an 
IL-10 zurückging. Zusammenfassend konnten wir nachweisen, dass die Inhibierung 
von p38 in humanen Monozyten entzündungsfördernde Auswirkungen zur Folge hat 
und dass es eine bislang unbekannte Verbindung zwischen p38 und mTOR gibt, 
welche wichtig für die Regulation der angeborenen Immunantwort ist. 
  1
1 Introduction 
1.1 The immune system 
1.1.1 The innate immune system 
The innate immune system is crucial for the defense against infectious microbes. It 
has two major functions. Firstly, it responds initially to a microbe and prevents infection 
of the host and secondly, it activates the adaptive immune system. The components of 
the innate immune system are epithelial barriers (e.g. skin), effector cells (e.g. 
neutrophils, macrophages, dendritic cells), cytokines, and the complement system. 
The innate immune system recognizes microbes via so-called pattern recognition 
receptors (e.g. Toll-like receptors, Nod-like receptors, scavenger receptors) that are 
expressed in a wide variety of cell types. These pattern recognition receptors are 
stimulated by pathogen-associated molecular patterns (PAMPs), which represent 
characteristic microbial pathogens and are shared by classes of microbes. After 
receptor stimulation, an intracellular signaling pathway is started that leads to the 
expression of molecules important for the defense against microbes and onset of 
inflammation. 
The first steps in the process of inflammation include the recruitment of leukocytes 
such as neutrophils and granulocytes to the site of infection. This is mediated by 
adhesion molecules expressed on endothelial cells that lead to the tethering and rolling 
of the leukocytes on the endothelium. Subsequently, adherent leukocytes are 
stimulated by chemokines to migrate through the endothelium and accumulate in 
tissues. 
The recognition of the PAMPs by the pattern recognition receptors also promotes 
phagocytosis of the microbes. This process is mediated by neutrophils or 
macrophages. After recognition by the receptor, the plasma membrane encloses the 
microbe and forms an intracellular vesicle, named phagosome. After activation of the 
phagocytes by cell surface receptors, the phagosome fuses with the lysosome to form 
the phagolysosome and the phagocytosed microbes are killed by the enzymes ROS 
(reactive oxygen species) and NO (nitric oxide). At the same time, the activated 
macrophages perform two other important functions. Firstly, they secrete cytokines 
(TNF, IL-12 or IL-1) and secondly, they increase the expression of MHC (major 
histocompatibility complex) molecules and costimulators on their cell surface. Those 
are important steps in the onset of cell-mediated immunity (explained in detail below) 
[1]. 
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1.1.2 Adaptive immune system 
In contrast to the innate immune system, which recognizes many but a limited 
number of microbial products, the adaptive immune system recognizes a vast number 
of foreign substances. It is more specific than the innate immune system, has a 
memory function and provides a more sustained and stronger response. Two types of 
adaptive immunity are to be distinguished: humoral- and cell-mediated immunity. 
Humoral immunity is mediated by B lymphocytes, which recognize extracellular 
antigens and differentiate into plasma cells to produce antibodies. These antibodies 
can neutralize microbes, opsonize them to promote their phagocytosis or activate the 
complement system. Cell-mediated immunity is mediated by T lymphocytes. One 
subpopulation of these T lymphocytes are the CD4+ T lymphocytes. Depending on the 
microbe and the cytokines produced by the APCs (antigen-presenting cells), naive 
CD4+ T lymphocytes may differentiate either into Th1, Th2 or Th17 cells, which all 
have distinct effector functions. 
The response to microbes that reside within the phagosome is mediated by Th1 
cells. Those are activated by APCs, which display processed antigens of endocytosed 
microbes on their class II MHC molecules and also provide the necessary second 
signals (costimulatory molecules (e.g.CD86) and cytokines) for T-cell activation. The 
APC can either be a dendritic cell (it presents antigen to naive T-cells during the 
recognition phase), a macrophage or a B lymphocyte (they present antigen to 
differentiated T-cells during the effector phase). APCs are important linkers of innate 
and adaptive immune system. One of the most important functions of an activated Th1 
cell is to activate macrophages to kill phagocytosed microbes more efficiently. The 
activation is mediated by the secretion of the cytokine IFN-γ (Interferon-γ) and contact-
mediated signals (CD40L-CD40 interaction) [1]. 
1.1.3 Pro- versus anti-inflammatory cytokines 
Cytokines are proteins that can be produced by nearly all cells in response to 
microbes and other antigens. They play an important role in the regulation of 
inflammation, immune response and infection, as they serve to communicate 
information among inflammatory cells. Cytokines can be roughly divided into two 
classes: pro- and anti-inflammatory cytokines. While the proinflammatory cytokines 
(e.g. TNF, IL-1, IFN-γ, IL-12) can make a disease even worse, anti-inflammatory 
cytokines (e.g. IL-4, IL-10, IL-13) can suppress the production of the proinflammatory 
cytokines and therefore lead to healing of the disease. TNF-α and IL-1 mediate the 
acute host inflammatory response. They recruit monocytes and neutrophils to the site 
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of infection and enable their attachment by inducing the expression of adhesive 
molecules on vascular endothelial cells. IL-12 links innate and adaptive immune 
response, being produced by dendritic cells and macrophages in response to 
intracellular microbes and stimulating production of IFN-γ by T-cells and NK-cells.  
IFN-γ in turn activates macrophages to kill phagocytosed microbes. In contrast, IL-10 
inhibits host immune response or terminates the response after eradication of microbial 
infection by inhibiting macrophages and dendritic cells. It inhibits the production of  
IL-12 and down-regulates the expression of class II MHC molecules and costimulators. 
Thus, the ratio between pro- and anti-inflammatory cytokines affects the progress of a 
disease and a balance between them is a necessity in healthy organisms [1-2]. 
1.2 The p38MAPK 
1.2.1 MAPK cascade 
The MAPK (mitogen-activated protein kinase) cascade consists of three protein 
kinases (MAPK, MAPKK (MAPK-kinase) and MAPKKK (MAPKK-kinase)) and transmits 
extracellular signals to regulate intracellular processes (Figure 1) [3-4]. 
 
Extracellular stimuli Inflammatory cytokines, stress, growth factors
MAPKKK MEKK1-4, MLK3 Raf
MEKK1-4, 
TAK1, ASK1 MEKK2/3
MAPKK MKK3/4/6 MEK1/2 MKK4/7 MKK5
MAPK p38α/β/γ/δ ERK1/2 JNK1/2/3 BMK1
Effectors Transcription factors, kinases
 
Figure 1. MAPK signaling cascade 
MAPKKK can be activated by various extracellular stimuli. Afterwards, they phosphorylate 
MAPKK, which in turn activate a MAPK. The downstream effectors of MAPK are transcription 
factors and further kinases. Figure adapted from Thalhamer et al [5]. 
The MAPK family consists of four members, which are all serine/threonine kinases: 
p38, ERK (extracellular signal-related kinase), JNK (c-jun N-terminal kinase) and BMK1 
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(big MAPK 1) [6-7]. The MAPKs all share a dual phosphorylation motif Thr-X-Tyr and 
are phosphorylated and activated by their upstream MAPKKs [4, 8]. These MAPKKs 
can either be MEK1/2 (phosphorylate ERK), MKK3/6 (phosphorylate p38), MKK4/7 
(phosphorylate JNK) or MEK5 (phosphorylates BMK1) [8]. The amino acid placed 
between threonine and tyrosine in the tri-peptide phosphorylation motif plays an 
important role in the recognition of the MAPKs by their MAPKKs [6]. ERK and BMK1 
have a Thr-Glu-Tyr motif, p38 has a Thr-Gly-Tyr motif and JNK has a Thr-Pro-Tyr motif 
in its activation loop [8]. The MAPKKs also have a dual phosphorylation motif and are 
phosphorylated and activated by their specific MAPKKKs [8]. The MAPK cascade plays 
an important role in many cellular functions, such as cell differentiation, cell 
proliferation, apoptosis and cell migration [6, 8]. 
1.2.2 p38 MAPK subunits and signaling 
There exist four different isoforms of p38, namely p38α [9], p38β [10], p38γ [11] and 
p38δ [12]. They have a sequence homology of more than 60 % to each other. While 
p38α and p38β are expressed ubiquitously, p38γ and p38δ seem to be expressed 
more restricted. p38γ is exclusively expressed in lung, pancreas, kidney, testis, and 
epidermis, while p38δ is expressed in skeletal muscle, heart, lung, and thymus. While 
the functions of p38α and p38β include stress response, differentiation, inflammation 
and proliferation, p38δ and p38γ seem to have more specialized functions [3]. 
The p38 family members can be activated by osmotic shock, heat, ultraviolet light, 
endotoxin, hormones, inflammatory cytokines and other stresses [4, 8]. The type of 
activation of p38 varies in different cell lines and depends on the stimulus [7]. Beside 
MKK3 and MKK6, MKK4 was also described to activate the p38 MAPK [12]. Another 
possible mode of activation is the autophosphorylation via TAB1 (transforming growth 
factor-β-activated protein kinase 1 - binding protein 1) [7, 13]. 
The four p38 isoforms have different downstream substrates and are thought to be 
expressed in different compartments of the same cell [3, 14-15]. The two main 
substrates regulated by p38 are transcription factors and protein kinases [3, 7]. MK2 
(MAPK-activated protein kinase 2) was one of the first p38MAPK substrates identified 
[7, 16]. It plays an important role in the activation of HSP27 (small heat shock protein 
27) [17] and LSP1 (lymphocyte-specific protein1) [7, 18]. Furthermore, MK2 is 
important for the phosphorylation and inactivation of TTP (tristetraprolin), which is an 
mRNA destabilizer [19-20]. In its unphosphorylated form, TTP binds to AU-rich 
elements of mRNAs and leads to their degradation, but when phosphorylated, TTP 
does not bind, resulting in stable and translatable mRNAs [19-20]. Other protein 
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kinases regulated by p38MAPK are PRAK (p38 regulated/activated kinase) [21], MSK1 
(mitogen- and stress-activated protein kinase 1) [22] and MNK1 (MAPK signal–
integrating kinase-1) [7, 23-24]. Transcription factors regulated by p38 MAPK include 
ATF1/2/6 (activating transcription factor 1/2/6), p53, MEF2 (myocyte enhance factor 2) 
and ELK1 (E-26 like protein 1) [4, 7]. 
1.2.3 Role of p38 MAPK in inflammation 
A lot of evidence points to a central role of the p38 pathway in inflammatory 
processes. Most of the literature examined the role of p38α, while the other isoforms 
seem to play a more minor role for inflammation [14-15]. p38 is pivotal in the production 
of proinflammatory cytokines, such as TNF-α, IL-1β and IL-6 [14-15, 25]. The 
regulation of these cytokines by p38 occurs at transcriptional and post-transcriptional 
level. While transcription factors regulated by p38 are responsible for the transcriptional 
regulation, the p38/MK2/TTP axis seems to control the post-transcriptional regulation of 
these cytokines by inhibiting the mRNA turnover [4, 14, 26]. Moreover, p38 designates 
responsible for the regulation of COX-2 (cyclooxygenase-2), a crucial enzyme during 
the first steps of prostaglandin biosynthesis. Prostaglandins are involved in many 
inflammatory reactions [27]. 
In addition, p38 is also involved in the expression of VCAM-1 (vascular cell adhesion 
molecule-1) and NO (nitric oxide) that are both important inflammatory molecules. 
VCAM-1 is a cell surface and adhesion molecule and it mediates the recruitment of 
inflammatory cells, such as lymphocytes and monocytes, from the blood to the tissue 
[1, 28]. p38 was shown to be involved in the post-transcriptional regulation of this 
molecule [28]. NO is generated by the enzyme iNOS (inducible NO synthase) in 
response to TNF-α and IL-1. It was shown that the p38 pathway regulates the 
expression of this enzyme [15, 29]. 
1.2.4 p38MAPK inhibitors 
The p38 pathway plays an essential role in many inflammatory diseases, such as 
rheumatoid arthritis, psoriasis or Crohn’s disease. Due to its involvement in these 
diseases, the p38 MAPK has been thought to be a favorable target for anti-
inflammatory drug therapy and a lot of effort has been made to generate p38 inhibitors 
[3-4, 30]. 
There exist two types of p38 inhibitors that differ in their way of binding to p38 
(Figure 2): pyridinyl-imidazoles as well as diaryl urea compounds. While the pyridinyl-
imidazoles, such as SB203580 ([4-(4´-fluorophenyl)-2-(4´-methylsulfinylphenyl)-5-(4´-
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pyridyl) imidazole]), are ATP competitive inhibitors [31], the diaryl compounds, such as 
BIRB0796 (1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) 
naphthalen-1-yl]urea) are allosteric inhibitors [32]. 
 
PP P
P
+ ATP
Substrate
No ATP bound
Inactive MAPK
ATP binds
TGY motif is
phosphorylated
Conformational change
Substrate can bind
Substrate-binding site
ATP-binding site
TGY motif
Activation of p38MAPK
+ ATP
Inhibitor occupies
ATP-binding site
ATP cannot bind
p38 MAPK
remains inactive
SB203580
Inhibition by ATP-mimicking inhibitors (e.g. SB203580)
+ ATP
Inhibitor binds next to
the ATP-binding site
Conformational change
in ATP-binding site
ATP cannot bind
p38 MAPK
remains inactive
BIRB0796
Inhibition by allosteric inhibitors (e.g. BIRB0796)
 
Figure 2. Mechanisms of p38MAPK activation and inhibition 
ATP binds to the ATP-binding site and phosphorylates the TGY motif. This causes a 
conformational change, which enables the substrate to bind. SB203580 binds to the ATP-
binding site and prevents binding of ATP. In contrast, BIRB0796 binds allosterically to the ATP-
binding site. This induces a conformational change, which inhibits the binding of ATP. 
Therefore, p38 remains inactive. Figure adapted from Coulthard et al [3]. 
The ATP competitive inhibitors only inhibit the p38α and p38β isoforms, while they 
fail to inhibit the p38γ and p38δ isoforms [3]. This is due to their requirement of 
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methionine 109 in the ATP-binding site that is lacking in p38γ and p38δ. This 
methionine residue is necessary to stabilize the interaction between the ATP-binding 
site and the inhibitor [3, 33]. 
Allosteric inhibitors, such as BIRB0796, inhibit all four isoforms of p38 by indirectly 
competing with ATP [34]. They bind next to the ATP-binding site and cause a 
conformational change that is incompatible with the binding of ATP [32]. 
Most of the clinically developed p38 inhibitors proved efficacy in blocking the 
production of proinflammatory cytokines in vitro and in animal models. Some of the 
inhibitors were evaluated in early phase clinical trials and only some of them reached 
phase III trials. Most of the clinical trials had to be stopped because of a lack of 
efficacy, safety issues, or unwanted side effects. Surprisingly, some of the inhibitors 
even showed an unexpected appearance of inflammatory events [3-4, 14, 35-36]. 
1.3 The mammalian target of rapamycin 
1.3.1 Role of mTOR 
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase 
with a molecular weight of 290 kDa. It belongs to the PIKK (phosphatidylinositol kinase-
related kinase) family of proteins and has important functions in survival, metabolism, 
growth, proliferation, and aging of a cell [37-39]. 
1.3.2 mTOR signaling 
The mTOR pathway can be activated by both extracellular and intracellular stimuli, 
including nutrients, growth factors, TLR ligands and varying energy levels. One of the 
best examples for the activation of mTOR is the stimulation of the insulin receptor that 
leads to the recruitment of PI3K (phosphoinositide 3-kinase) to the plasma membrane. 
Subsequently, PIP2 (phosphatidylinositol 4,5-bisphosphoate) is phosphorylated by 
PI3K, thereby generating PIP3 (phosphatidylinositol-3,4,5-trisphosphate) [37, 40]. 
Afterwards, PIP3 recruits the downstream Akt, which is phosphorylated by PDK1  
(3-phosphoinositide-dependent protein kinase-1) [41]. Akt, also known as PKB (protein 
kinase B), is one of the most important survival kinases and exists in three isoforms 
(Akt1, Akt2 and Akt3). They are involved in the regulation of various cellular processes, 
such as growth, metabolism, apoptosis and proliferation [37, 39, 42]. Downstream of 
Akt is TSC2 (tuberous sclerosis complex protein 2), which is a negative regulator of 
mTOR. TSC2 is in a complex with TSC1 and has important tumor suppressive 
functions [37, 39]. The TSC1/TSC2 complex blocks Rheb (Ras homolog enriched in 
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brain), which is an important activator of mTOR [43]. After phosphorylation by Akt, 
TSC2 is inactivated, leading to a loss of suppression of Rheb. Subsequently, Rheb 
activates mTOR [37, 39, 44]. The two best characterized downstream effectors of 
mTOR are 4E-BP1 (eIF4E-bindig protein 1) and p70S6K (p70 ribosomal protein S6 
kinase 1) (Figure 3). Phosphorylation by mTOR restrains 4E-BP1 from binding eIF4E 
(eukaryotic translation initiation factor 4E), which is important in the initiation of cap-
dependent mRNA translation. Activation of p70S6K leads to the phosphorylation of the 
ribosomal protein S6. Thus, mTOR has a crucial function in protein translation [37, 39, 
45]. 
 
TLR ligands, insulin, IGF-1
PI3K
PDK1
Akt
TSC2 TSC1
Rheb
mTORC2
mTOR
Rictor
SIN1
mLST8 
Rapamycin
FKBP12 mTORC1
mTOR
Raptor
mLST8 
P
P
p70S6K 4E-BP1
P P
P
PIP3
PIP2
Wortmannin
Ser437
Thr308
Protein translation and cell growth
 
Figure 3. The PI3K/Akt/mTOR pathway 
TLR ligands and growth factors stimulate their receptors, which leads to the recruitment of PI3K. 
This kinase converts PIP2 to PIP3 by phosphorylation. PDK1 is recruited and Akt is 
phosphorylated at Thr308. Akt can also be activated by mTORC2. Phosphorylated Akt 
phosphorylates TSC2, thus inhibiting the TSC1/TSC2 complex to activate Rheb. Rheb 
stimulates mTORC1 activity, which is sensitive to rapamycin. Downstream of mTORC1 are 
p70S6K and 4E-BP1. Activated mTORC1 is important for protein translation and cell growth. 
Figure adapted from Weichhart et al and Yang et al [37, 39]. 
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1.3.3 Two complexes of mTOR 
There exist two distinct complexes of mTOR that differ in their composition: 
mTORC1 (mTOR complex 1) and mTORC2. While mTORC1 is composed of mTOR, 
raptor (regulatory-associated protein of mTOR) and mLST8, mTORC2 is made up of 
mTOR, rictor (rapamycin-insensitive companion of mTOR), mLST8 and Sin1 [37, 46-
47]. In contrast to mTORC2, mTORC1 is sensitive to rapamycin, which is thought to 
block the interaction between mTOR and raptor [37, 46, 48]. Subsequently, p70S6K 
and 4E-BP1 are not recruited and remain unphosphorylated. mTORC2 has recently 
been shown to phosphorylate Akt at Ser473 and is therefore thought to be upstream of 
mTORC1 [37, 49]. 
1.3.4 Inhibition of mTOR by rapamycin 
In 1975, the bacterial strain Streptomyces hygroscopicus was isolated from a soil 
sample from the Easter Islands. This strain was found to produce a potent anti-fungal 
metabolite, which was named rapamycin, after Rapa Nui (Easter Island in the local 
language) [38, 39]. 
 
Rapamycin
T cell
MΦ
Th1 or
Th17
mDC
Proinflammatory
response
IL-12
IL-23
IL-10
promo
tes dif
ferent
iation
Inhibition of clonal
expansion
LPS
 
Figure 4. Effects of rapamycin on different cell types 
In T-cells, rapamycin decreases the proliferation by inhibiting cell cycle progression. In 
macrophages and mDCs pretreatment with rapamycin and stimulation with LPS induces a 
proinflammatory immune response. Figure adapted from Janes et al [50]. 
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Later on, rapamycin was found to have potent immunosuppressive and anti-
proliferative activities and in 1999 it became an FDA (Food and Drug Administration)-
approved drug [37, 51]. Rapamycin proved efficacious in organ transplantation to 
prevent allograft rejection [37]. Rapamycin and its analogs are also currently evaluated 
as anticancer agents [52]. 
Rapamycin acts on mTORC1 by forming a complex with FKBP12 (FK506-binding 
protein 12), thereby blocking the interaction between mTORC1 and Raptor [37, 39, 53-
54]. In T lymphocytes stimulated with IL-2, rapamycin was found to decrease 
proliferation by inhibiting cell cycle progression [55]. This explains the 
immunosuppressive and anti-tumor activities of mTOR [56]. 
1.3.5 mTOR in inflammation 
In contrast to the beneficial, immunosuppressive effects of rapamycin during 
transplantation, some side effects became apparent with the increased usage of 
rapamycin. Different inflammatory events occurred after usage of the agent [56-59]. 
This pointed to a role of mTOR in the regulation of inflammation. 
Based on these reports, a lot of effort was made revealing mTOR as a central player 
in the regulation of the innate immune response [37, 50]. It was shown that inhibition of 
mTORC1 after TLR stimulation raises IL-12p40, IL-12p70 and IL-23 levels while 
impairing IL-10 levels in monocytes, macrophages and myeloid dendritic cells [60-61]. 
Weichhart et al. showed that the downregulation of IL-10 is mediated via the 
transcription factor STAT3 (signal transducer and activator of transcription 3) and the 
upregulation of IL-12p40 is regulated by NF-κB [61]. This proinflammatory action of 
rapamycin on APCs enhances their ability to stimulate T-cells. [37]. It was shown that 
rapamycin-treated monocytes promote the induction of Th1 and Th17 cells, indicated 
by the augmentation of IL-17 and IFN-γ cytokine levels after T-cell stimulation. In line 
with that, rapamycin protected Listeria monocytogenes-infected Balb/c mice from death 
by enhancing IL-12 and IFN-γ production [61]. 
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2 Aim of the study 
mTOR was recently found to be a critical regulator of IL-12/IL-10 production in the 
innate immune system. Inhibition of mTOR by rapamycin increases the levels of  
IL-12p40 in human monocytes, while it attenuates the levels of IL-10 [60-61]. 
The p38MAPK is involved in the regulation of IL-12p40. This regulation can either be 
positive or negative, depending on the cell type and stimulus [62]. Recently, it was 
shown that inhibition of p38 with SB203580 enhances the expression of IL-12p40 in 
primary human monocytes after stimulation with LPS, while it decreases the levels of 
IL-12p40 in THP-1 cells [63]. 
In face of the fact that p38 inhibitors evoked unexpected inflammatory side effects in 
clinical trials and due to the comparable effects of mTOR and p38 inhibition on the 
cytokine milieu in human monocytes, we assumed that p38 may play a role in 
regulating mTOR mediated immune response. As a molecular link of p38 and mTOR is 
unknown, we were interested in the consequences of inhibiting p38 or mTOR signaling 
for the inflammatory response and its connections. Finally, we wanted to understand 
the functional consequences of modulating mTOR and p38 in innate immunity for the 
subsequent effects on the adaptive immune response, both in vitro and in vivo. As p38 
consists of four subunits, we were also interested in the question which subunit is 
responsible for a potential regulation of mTOR. 
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3 Material and methods 
3.1 Media, buffers and solutions 
RPMI + 10 % FCS + Glutamine + Pen/Strep 
? RPMI 1640 (Gibco-BRL Life Technology) 
? 2 mM L-glutamine (Gibco) 
? 100 µg/ml streptomycin (Gibco) 
? 100 U/ml penicillin (Gibco) 
? 10 % FCS (Hyclone) (inactivated at 56°C for 30 min) 
 
RPMI complete medium 
? RPMI 1640 (Gibco-BRL Life Technology) 
? 2 mM L-glutamine (Gibco) 
? 100 µg/ml streptomycin (Gibco) 
? 100 U/ml penicillin (Gibco) 
? 10 % FCS (Hyclone) (inactivated at 56°C for 30 min) 
? 50 µM 2-Mercaptoethanol (Sigma) 
? 100 µM Non Essential Amino Acids (GIBCO) 
? 1 mM Sodium Pyruvate (GIBCO) 
 
DMEM + 10 % FCS + Glutamine + Pen/Strep  
? Dulbecco’s Modified Eagle Medium (Dulbecco) 
? 4.5 g/L glucose (Sigma) 
? 2 mM L-glutamine (Gibco) 
? 100 µg/ml streptomycin (Gibco) 
? 100 U/ml penicillin (Gibco) 
? 10 % FCS (Hyclone) (inactivated at 56°C for 30 min) 
 
10x Hemolysis buffer 
? 90 g/L NH4Cl (Merck) 
? 10 g/L KHCO3 (Merck) 
? 0.37 g/L EDTA-Na2 (Sigma) 
? Dilute in 800 ml dH2O, adjust pH to 7.3 
? dH2O ad 1000 ml 
? Sterilize by filtration 
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1x Hemolysis buffer 
? 100 ml 10x Hemolysis buffer 
? 900 ml sterile H2O 
 
1x PBS 
? 100 ml 10x PBS (without Ca2+ / Mg2+) (Lonza) 
? 900 ml dH2O 
 
1x PBS-Tween (PBS-T) 
? 100 ml 10x PBS 
? 1 ml Tween 20 (Biorad) 
? 899 ml dH2O 
 
50x Phosphatase inhibitor 
? 500 mM NaF (Merck) 
? 100 nM Na4P2O7 (Merck) 
? 100 mM Glycerophosphat (Sigma) 
? 10 mM Na3VO4 (Sigma) 
? store at 4°C 
 
10x protease inhibitor 
? 1 Protease inhibitor cocktail tablet (Roche) 
? 2 ml dH2O 
? Freeze aliquots at -20°C 
 
2x Hepes buffer  
? 20 mM Hepes (Sigma) 
? 140 mM NaCl (Merck) 
? 2 mM EDTA (Sigma) 
? pH7.9 
 
Stripping Buffer 
? 62.5 mM Tris-HCl pH 6.8 
? 2 % SDS (GE-Healthcare) 
? 100 mM 2-Mercaptoethanol (Sigma) 
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Tx-100 Lysis Buffer (10ml) 
? 5 ml 2x Hepes buffer 
? 1 ml 10x Protease Inhibitor 
? 0.2 ml 50x Phosphatase Inhibitor 
? 1 ml 10 %Tx-100 (Sigma) 
? 2.8 ml dH2O 
 
4x Reducing Sample Buffer 
? 250 mM Tris-HCl pH 6.8 
? 40 % Glycerol (Sigma) 
? 8 % SDS (GE-Healthcare) 
? 400 mM Dithiothreitol (Sigma), added fresh 
? Stain with bromphenolblue (Sigma) 
 
5x Running Buffer 
? 15.14 g/L Tris (Sigma) 
? 72.07 g/L Glycin (Fluka) 
? 5 g/L SDS (GE-Healthcare) 
? dH2O ad 1000 ml 
 
1x Running Buffer 
? 200 ml 5x Running Buffer 
? 800 ml dH2O 
 
5x Transfer Buffer 
? 15.14 g/L Tris (Sigma) 
? 72.07 g/L Glycin (Fluka) 
? dH2O ad 1000 ml 
 
1x Transfer Buffer 
? 200 ml 5x Transfer Buffer 
? 200 ml Methanol (Fisher chemical) 
? 600 ml dH2O 
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Acrylamide gels 
Stack (10ml) 7.5 % (10ml) 10 % (10ml) 12 % (10ml)  
1.33 ml 2.50 ml 3.33 ml 4.00 ml 30 % AA/Bis (Biorad) 
2.50 ml - - - 0.5 M Tris-HCl, pH6.8 
- 2.50 ml 2.50 ml 2.50 ml 1.5 M Tris-HCl, pH8.8 
0.10 ml 0.10 ml 0.10 ml 0.10 ml 10 % SDS 
6.07 ml 4.90 ml 4.07 ml 3.40 ml dH2O 
10 µl  10 µl  10 µl  10 µl  TEMED (Biorad) 
50 µl  50 µl  50 µl  50 µl  10 % APS (Amersham)
Table 1. Recipes for stacking and resolving gels used in SDS-PAGE. 
 
 
4 % PFA in PBS 
? 1.85 g Paraformaldehyde (Fluka) 
? 3.5 ml dH2O 
? 10 µl 10 M NaOH (Merck) 
? 65°C water bath 
? Dilute in 41.25 ml PBS 
 
LBAmp medium 
? 25 g Luria Broth (Sigma) 
? 1 L dH2O 
? Autoclave at 121°C for 15 min 
? Cool down to approximately 50°C 
? Add 100 µg/ml Ampicillin (Sigma) 
 
LBAmp plates 
? 32 g LB Agar (Lennox L Agar, Invitrogen) 
? 1 L dH2O 
? Autoclave at 121°C for 15 min 
? Cool down to approximately 50°C 
? Add 100 µg/ml Ampicillin (Sigma) 
? Pour into 10 cm petri dishes (BD Falcon) 
? Store at 4°C 
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3.2 Methods 
3.2.1 PBMC isolation and MACS 
Peripheral blood mononuclear cells (PBMCs) were prepared from buffy coats by 
density gradient centrifugation using Ficoll-PaqueTM Plus (GE-Healthcare). Ficoll, a 
hydrophilic polysaccharide, has a density of 1.077 g/ml. This is bigger than the density 
of lymphocytes and monocytes, but smaller than the density of erythrocytes, 
granulocytes and thrombocytes. Therefore, the mononuclear cells are enriched in a 
layer above the ficoll layer, while the erythrocytes, granulocytes and thrombocytes can 
be found on the bottom of the tube, when being centrifuged. 
Human blood was diluted with PBS in a 1:1 ratio and 35 ml of the suspension were 
laid over 14 ml Ficoll-Paque in a 50 ml conical tube. After centrifugation at 544 g and 
room temperature for 30 min, the mononuclear cell layer was transferred to a new  
50 ml tube. After a washing step with MACS-buffer (Miltenyi Biotec) and centrifugation 
at 544 g and 4°C, red blood cells were lysed for 5 min on ice with 5 ml hemolysis 
buffer. After another two washing steps PBMCs were counted and either taken up in 
medium or prepared for CD14+ MACS magnetic cell sorting. When preparing for 
CD14+ MACS magnetic cell sorting, cells were again washed two times in MACS-
buffer and incubated with 100 µl CD14 Microbeads (Miltenyi)/1x 108 cells in 800 µl 
MACS-buffer/1x 108 cells for 15 min at 4°C. After washing in MACS-buffer, cells were 
resuspended in 500 µl MACS-buffer/1x 108 cells and loaded on an LS-separation 
column (Miltenyi), which was first placed on a magnetic cell separator (quadro MACS, 
Miltenyi). After loading, the column was washed 3 times with 5 ml MACS-buffer each 
and flow-through was collected as the non-magnetic fraction. Then, CD14+ cells were 
isolated from the column by removing it from the magnetic cell separator and pushing a 
plug into the column. CD14+ cells were counted, washed twice in RPMI medium and 
taken up in RPMI + 10 % FCS + Glutamine + Pen/Strep. They were allowed to rest at 
37°C and 5 % CO2 for 30 min before stimulation. 
In order to obtain myeloid dendritic cells (mDCs), the CD1c (BDCA-1) Dendritic Cell 
Isolation Kit (MACS, Miltenyi) was used. The flow-through of the CD14+ MACS was 
washed twice in MACS-buffer (centrifugation at 300 g, 4°C and 10 min) and the 
supernatant was removed. Cells were incubated with 100 µl FcR Blocking Reagent, 
100 µl CD19 Microbeads and 100 µl CD1c Biotin Antibody in 200 µl MACS-buffer per 
1x 108 cells. The incubation was performed for 15 min at 4°C. Afterwards, the cells 
were again washed twice as described and the supernatant was removed. The pellet 
was resuspended in 500 µl MACS-buffer/1x 108 cells and loaded on an LD-separation 
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column to deplete B-cells. The column was rinsed twice with 1 ml MACS-buffer and the 
flow-through was harvested. The cells in the flow-through were counted, washed in 
MACS-buffer as described and the supernatant was removed. Afterwards, the pellet 
was incubated with 100 µl Anti-Biotin Microbeads in 400 µl MACS-buffer per  
1x 108 cells. The solution was incubated on ice for 15 min, followed by washing two 
times with MACS-buffer. The pellet was resuspended in 500 µl MACS-buffer per  
1x 108 cells and loaded on an LS-separation column. The column was rinsed three 
times with 3 ml MACS-buffer. Afterwards, the column was removed from the cell 
separator and a plug was pushed into the column to obtain the positive selected cells 
(=CD1c+). The cells were washed twice in RPMI medium and taken up in RPMI +  
10 % FCS + Glutamine + Pen/Strep and further treated as indicated. 
For the T-cell differentiation assay, the PBMCs without the positive selected  
CD14+ monocytes were used. Therefore, the flow-through of the CD14+ MACS-
procedure was centrifuged at 500 g and 4°C for 7 min, washed twice in RPMI medium 
and taken up in RPMI complete medium. Until use, the cells were stored at a 
concentration of 2x106/ml in the fridge over night. 
3.2.2 Cell culture 
Cells were cultured in an incubator at 37°C and 5 % CO2. CD14+ monocytes were 
isolated from whole blood as described and taken up in RPMI + 10 % FCS + Glutamine 
+ Pen/Strep. Before stimulation, they were allowed to rest for 30 min. mDCs were 
treated the same way as monocytes. 
In order to obtain monocyte derived dendritic cells (moDCs), 4x106 monocytes were 
seeded in a well of a 6-well plate (TPP) at a concentration of 1x106/ml and stimulated 
with 50 ng/ml GM-CSF (Peprotech) and 10 ng/ml IL-4 (Peprotech) for one week. After 
one week, the cells were splitted to 24-wells (Nunclon) and stimulated as indicated. 
Mouse embryonic fibroblasts (MEFs) were cultured in DMEM + 10 % FCS + 
Glutamine + Pen/Strep. Tsc2+/+ p53-/- and Tsc2-/- p53-/- MEFs were a kind gift of 
David Kwiatkowski. Freezing stocks of these cells were thawed at 37°C and washed 
once in DMEM. After the procedure, the cells were seeded in a 10 cm tissue culture 
dish (Iwaki). The cells were passaged by trypsinization. For this, the medium was 
removed and cells were washed once with PBS. PBS was removed and 1 ml trypsin-
EDTA was added to the plate. The plate was incubated at 37°C and 5 % CO2 for 3 min. 
After that, the trypsinization was stopped by adding medium and cells were splitted 
1:10 to new plates. Before stimulation of the MEFs, they were splitted as described to 
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12- or 24- wells, allowed to adhere and starved over night in DMEM + Glutamine + 
Pen/Strep without FCS. 
Bone marrow of p38α fl/fl and p38α fl/fl LysMCre ∆p38α mice was a kind gift of Jin 
Mo Park. The bone marrow was thawed at 37°C and cultured in RPMI complete 
medium + 10 % L929 culture supernatant in a petri dish (BD Falcon). After three days, 
supernatant was removed from the petri dish and bone marrow derived macrophages 
(BMDMs) were washed with PBS and new medium was added. The macrophages 
were then scraped from the plate and splitted to two new petri dishes. After another 
three days, cells were again washed with PBS and RPMI complete medium with 2 %, 
instead of 10 % FCS, was added. Cells were splitted to 24- or 6-wells and starved over 
night, before being stimulated as indicated. 
3.2.3 Cell stimulation 
Monocytes, moDCs, mDCs, macrophages and MEFs were pretreated for 90 min 
with the indicated concentrations of wortmannin (Sigma), SB203580 (Tocris 
Bioscience), BIRB0796 (Axon Medchem), SD169 (Calbiochem), rapamycin 
(Calbiochem), mithramycin (Sigma), DMSO (Sigma) or different combinations of them. 
After the pretreatment, cells were stimulated for the indicated times with 
lipopolysaccharide from Escherichia coli 0111:B4 (LPS), anisomycin from 
Streptomyces griseolus, zymosan A from saccharomyces cerevisiae (all from Sigma), 
IFN-γ (R&D), Staphylococcus aureus cells (SAC, Calbiochem), heat-killed Listeria 
monocytogenes (a kind gift of Dr. Caroline Lassnig), UV light or different combinations 
of them. In case of the UV light stimulation, the plates were placed on a 20x20 UV-
transilluminator (MWG Biotech) and activated with UV light for 10 sec or 1 min. After 
the activation, cells were incubated at 37°C and 5 %CO2 for the indicated times. 
To investigate intracellular signaling, cells were stimulated for 30 min or 1 h and 
further treated as described. For determination of mRNA levels, cells were activated for 
2 h, 4 h or 6 h and further proceeded as described. In order to measure cytokine levels, 
cells were stimulated for 24 h. 
3.2.4 T-cell differentiation assay 
In order to investigate the T-cell response elicited by differently pretreated 
monocytes, we adapted a T-cell differentiation assay protocol from Acosta-Rodriguez 
et al [64]. Monocytes were isolated from whole blood as described and seeded in  
24-well plates in RPMI + 10 % FCS + Glutamine + Pen/Strep. They were allowed to 
rest for 30 min at 37°C, 5 % CO2. Afterwards, monocytes were incubated with medium, 
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200 nM BIRB0796, 2 µM SB203580 or 100 nM rapamycin for 90 min and stimulated 
with 100 ng/ml LPS for 24 h. The cells were then washed with PBS and incubated with 
allogeneic T lymphocytes at a ratio of 1:1 in 24-well plates in RPMI complete medium. 
After one week, cell-free supernatants were taken off and IFN-γ, IL-17 and IL-4 
production was determined by Luminex as described. The cells were activated for 5 h 
with 50 ng/ml phorbol-12-myristat-13-acetat (PMA) and 200 ng/ml ionomycin (both from 
Sigma) in the presence of 10 µg/ml brefeldin A (Sigma) for the last 3 h. Afterwards, 
cells were transferred to FACS-tubes and flow cytometry was performed as described. 
3.2.5 Immunocytochemistry 
Cells were cultured in 8-well PermanoxTM chamber slides (Lab-Tek Chamber Slide 
System) and pretreated as indicated. After stimulation, the culture medium was 
replaced with a freshly prepared solution of 4 % PFA in PBS and cells were fixed for  
10 min at room temperature. The chambers were then removed from the slides and the 
cells were rinsed once with PBS. In order to quench the PFA, cells were incubated with 
100 nM glycine in PBS for 15 min. Afterwards, cells were washed in PBS for 30 min. 
The next step was to permeabilize the cells by incubating them with methanol for 5 min 
at -20°C. After rinsing with PBS, slides were again washed with PBS for 30 min at room 
temperature. In order to block unspecific sites, cells were incubated with 1 % BSA in 
PBS for 1 h at room temperature. Afterwards, the primary antibody was added to the 
slides over night at 4°C in a humidity chamber. 
 
Primary antibodies Dilution Origin Company 
p-MK2 (Thr334) 1:50 in PBS + 1%BSA + 0.02%NaN3 
rabbit Cell signaling 
p-S6 (240/244) 1:50 in PBS + 1%BSA + 0.02%NaN3 
rabbit Cell signaling 
Secondary antibodies    
Anti-rabbit 
Alexa Fluor 488 1:200 in PBS goat Invitrogen 
Table 2. Primary and secondary antibodies used for immunofluorescence. 
 
After removing the primary antibody dilution and rinsing the slides with PBS, cells 
were washed three times with PBS for 20 min. Following, cells were incubated with 
secondary antibody dilutions in PBS for 1 h at room temperature in the dark. After 
rinsing and washing the slides twice with PBS for 20 min, nuclei were stained with  
0.1 µg/ml Hoechst-33342 (Invitrogen) in dH2O. After 5 min of incubation, the slides 
were rinsed and washed with PBS for another 20 min. PBS was removed completely 
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and slides were mounted with mounting medium (Vectashield H-1000). Finally, slides 
were sealed with nail polish and images were taken on a fluorescence microscope 
(Olympus Provis AX-70) equipped with a digital camera (Olympus XC-50). 
3.2.6 Preparation of Western Blot samples 
Cells were pretreated in 6- or 12-well culture plates (Falcon, BD Biosciences) as 
indicated. After stimulation, cells were washed once with PBS and taken up either in 
100 µl Triton X-100 Lysis Buffer or direct in 60 µl 1x SDS reducing sample buffer per 
well on ice. When taken up in 1xSDS reducing sample buffer, samples were kept on 
ice for 10 min and were then boiled for 5 min at 95°C. When cells were taken up in 
Triton X-100 Lysis Buffer, they were sonicated three times for 10 sec, 10 % Output  
(2 mm tip) and kept on ice for 30 min. Tubes were shaken regularly. After incubation on 
ice, cell debris was pelleted by centrifugation for 10 min, at 16000 g and 4°C. The 
supernatant was transferred to a new 1.5 ml tube and protein concentration was 
measured by using the BCA Protein Assay Kit (Thermo Scientific), according to the 
manufacturer’s protocol. Western samples were prepared by adjusting the protein 
concentration with lysis buffer and adding 4xSDS reducing sample buffer. Samples 
were boiled for 5 min at 95°C and stored at -20°C until analysis by Western Blot. 
3.2.7 RNA extraction and cDNA synthesis 
Cells were pretreated as indicated. Total RNA was extracted in 500 µl TRIzol 
(Invitrogen). RNA was isolated as follows: 120 µl ddH2O (Sigma) and 100 µl chloroform 
(Merck) were added to the 500 µl TRIzol phase in a 2 ml tube. After vortexing, the 
mixture was incubated at room temperature for 10 min, following centrifugation for  
15 min at 13000 rpm and 4°C. The aqueous phase was transferred to a new 1.5 ml 
tube and 1 µl glycoblue (Ambion) was added. 280 µl cold isopropanol (Merck) were 
added, the tube was again vortexed and then incubated on ice for 30 min. 
Centrifugation for 30 min at 13000 rpm and 4°C followed. The supernatant was 
removed and the pellet was washed with 75 % EtOH (Merck). After drying the pellet, it 
was dissolved in 20 µl RNase free H2O (Sigma) and cDNA was generated as follows:  
8 µl 5xFirst Strand Buffer (Invitrogen), 4 µl 0.1 M DTT (Invitrogen), 2 µl 10 mM dNTPs 
(prepared from 100 mM dATP, dGTP, dCTP, dTTP (all from Invitrogen)), 2 µl 100 ng/ml 
Random Hexamers (Invitrogen) and 1 µl RNase OUT Inhibitor (Invitrogen) were added 
to the 20 µl H2O and the tube was placed in a thermocycler at 65°C for 15 min. After 
the 15 min, 1 µl Superscript II (Invitrogen) was added and the reverse transcription was 
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started with the following program: 50 min at 42°C; 15 min at 70°C and cooling to 4°C. 
The cDNA was stored at -20°C until further use. 
3.2.8 Flow cytometry 
Cells were stimulated as indicated, transferred to FACS-tubes (Matrix) and kept on 
ice. After centrifugation at 300 g and 4°C for 5 min, supernatant was discarded and 
cells were washed with cold PBS. After another round of centrifugation and discarding 
the supernatant, cells were blocked with 1 µl beriglobin P (Behring) in 49 µl PBS for  
10 min on ice. Following, tubes were filled with PBS and again centrifuged at 300 g and 
4°C for 5 min. Afterwards, cells were incubated with 1 µl anti-CD4+ (BD Bioscience) in 
49 µl PBS on ice for 30 min in the dark. Cells were again washed with PBS and 
centrifuged as described above. In order to fix and permeabilize the cells, we used the 
Fix & Perm Cell Permeabilization Kit (BD Bioscience) according to the manufacturer’s 
protocol. Cells were incubated with 50 µl solution A (fixing solution)/sample for 15 min 
at room temperature, washed with PBS and then centrifuged as indicated. Afterwards, 
1 µl of the respective antibody was dissolved in 49 µl solution B (permeabilizing 
solution) and added to the tube. The cells were incubated for 15 min at room 
temperature and washed with PBS. After centrifuging and discarding the supernatant, 
the cells were taken up in 50 µl PBS and analyzed on a FACSCanto II (BD Bioscience). 
 
Antibodies conjugate Clone Company 
IFN-γ FITC 4S.B3 BD Bioscience 
IL-4 PE 8D4-8 BD Bioscience 
CD86 PE IT2.2 Pharmingen 
HLA-DR PerCP L243 BioLegend 
Lineage cocktail 1 
(CD3, CD14, CD16, CD19, 
CD20, CD56) 
FITC 
SK7, 3G8, SJ25C1, 
L27, MφP9, 
NCAM16.2 
BD Bioscience 
CD11c APC 3.9 BioLegend 
Table 3. Antibodies used for flow cytometry. 
 
3.2.9 Real-Time PCR 
For the real-time PCR analysis, TaqMan Gene Expression Assays (Applied 
Biosystems) were used. 9 µl master mix, consisting of 5 µl TaqMan Universal PCR 
Master Mix 2x, 0.5 µl Assay Mix 20x and 3.5 µl ddH2O, were mixed with 1 µl cDNA in a 
MicroAmp optical 96-well reaction plate (Applied Biosystems). Reactions were 
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performed in duplicates. After sealing the plate, it was transferred into an ABI Prism 
7000 and the following program was performed: 10 min at 95°C; 40x [15 sec at 95°C;  
1 min at 60°C]. 
Expression levels of target mRNAs were normalized to ubiquitin and are shown as 
fold increase to unstimulated control. The following PCR primers and TaqMan MGB 
probes (FAM-labeled) were used: IL-10 (human, assay ID: Hs00174086_m1); IL-12p40 
(human, assay ID: Hs00233688_m1); IL-23p19 (human, assay ID: Hs00372324_m1); 
TNF-a (human, assay ID: Hs00174128_m1); UBC (human, assay ID: 
Hs00824723_m1); IL-12p40 (mouse, assay ID: Mm00439616_m1); IL-10 (mouse, 
assay ID: Mm01201237_m1) and UBC (mouse, Mm01288993_m1). 
3.2.10 SDS-PAGE and Western Blot 
Before protein samples were loaded and SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) was started, they were boiled for 5 min at 95°C and 
centrifuged at 16000 g and room temperature for 5 min. Next, the electrophoresis 
apparatus was set up and 10 µg protein per lane were loaded on a 7.5 %, 10 % or  
12 % gel as desired. After electrophoresis, the gel was blotted on either a nitrocellulose 
(Whatman, Protran) or PVDF (Millipore) membrane. Before using the membranes, they 
were pre-wetted in 1x transfer buffer. The PVDF membrane was pre-wetted for 30 sec 
in methanol and then kept for 10 min in 1x Transfer buffer. Blotting was performed for 
40 min at 15 V using the Trans-Blot SD semi-dry electrophoretic transfer cell 
(BIORAD). In order to investigate the blotting efficiency, membranes were rinsed with 
H2O and stained with Ponceau S (Sigma) for 1 min. Ponceau S detects proteins 
unspecifically. The Ponceau staining was removed by washing for 1 min with PBS-T. 
Afterwards, the membrane was blocked in 4 % dry milk (BIORAD) in PBS-T for 1 h. 
The primary antibody was added over night at 4°C. Primary antibody dilutions have 
been used several times and stored at 4°C until use. 
After washing three times for 10 min each with PBS-T, the membrane was 
incubated with the secondary antibody for 45 min at room temperature with 4 % dry 
milk in PBS-T. The secondary antibodies were conjugated with horseradish peroxidase 
(HRP). After another 3x 10 min wash step, Immobilon™ Western Chemiluminescent 
HRP Substrate was used to detect the antibodies. The reaction was visualized using 
Amersham Hyperfilm ECL (GE-Healthcare) and the AGFA Classic E.O.S. processor. 
When a membrane was incubated with more than one primary antibody, it was 
washed twice with PBS-T for 5 min and stripped with Stripping Buffer for 15 min in a 
  
23
 
50°C water bath. Afterwards, the membrane was blocked again in 4 % dry milk in PBS-
T for 1 h at room temperature. 
 
Primary  
antibodies Dilution Origin Company 
p38 MAPK 1:500 in PBS-T + 0.02%NaN3 rabbit Santa Cruz 
p-p38 (Thr380/Tyr382) 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p38α MAPK 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p38β MAPK 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p38σ MAPK 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-S6 (240/244) 1:2000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
S6-ribosomal protein 1:1000 in PBS-T + 0.02%NaN3 mouse Cell signaling 
p-4E-BP1 (Thr37/46) 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
4E-BP1 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-p70S6K (Thr389) 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p70S6K 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-Erk (Tyr204) 1:500 in PBS-T + 0.02%NaN3 mouse Santa Cruz 
GAPDH 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
c-Jun 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-Akt (Ser437) 1:500 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-MK2 (Thr334) 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
p-GSK3β (Ser9) 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
IkBα 1:500 in PBS-T + 0.02%NaN3 rabbit Santa Cruz 
Histon H3 1:1000 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
Tuberin/TSC2 1:500 in PBS-T + 0.02%NaN3 rabbit Cell signaling 
Secondary antibodies    
Anti-rabbit 1:3000 in PBS-T + 4% dry milk donkey GE Healthcare 
Anti-mouse 1:10000 in PBS-T + 4% dry milk goat 
Bethyl 
Laboratories 
Table 4. Primary and secondary antibodies used for Western Blot. 
 
3.2.11 Escherichia coli transformation and plasmid preparation 
Sp1-Luc was a kind gift of Amyn Habib. Competent Escherichia coli (E. coli) DH5α 
(Sigma) were thawed on ice. 90 µl of the thawed cells and 1 µl of the plasmid were 
mixed in a 1.5 ml tube and incubated on ice for 5 min. Afterwards, a heat shock was 
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performed (45 sec, 42°C). Immediately after the heat shock, cells were incubated on 
ice for 2 min, followed by addition of 900 µl LB medium. The suspension was incubated 
on the thermomixer (Thermomixer 5436, eppendorf) with vigorously shaking. 10 µl of 
the suspension were plated on LBAmp plates and incubated at 37°C over night. 
One colony of the grown E. coli was picked from the plate, inoculated into 10 ml 
LBAmp medium and grown to mid log phase at 37°C. Afterwards, 2 ml of the suspension 
were inoculated into 250 ml LBAmp medium and incubated at 37°C over night. The next 
step was to transfer the 250 ml of the E. coli suspension into five 50 ml conical tubes 
(Sarstedt) and centrifuge them at 4°C and 4500 g for 30 min. The supernatant was 
removed and the pellet was stored at -20°C until further use for plasmid preparation. 
For the plasmid preparation, the EndoFree Plasmid Purification Maxi Kit (Quiagen) 
was used according to the manufacturer’s instructions. In the last step, the plasmid was 
dissolved in 100 µl TE-buffer (provided with the Kit) and the DNA concentration was 
measured with a NanoDrop ND-1000 Spectrophotometer (peQLab). The concentration 
was adjusted to 1 mg/ml with TE-buffer and the plasmid was stored at -80°C until 
further use. 
3.2.12 Reporter Gene Assay 
MEFs were cultured as described, splitted to 24-well plates and allowed to adhere 
over night. For transfection of the MEFs, 1 µl Lipofectamine Reagent (Invitrogen) and 
0.8 µg Sp1-Luc plasmid (1 mg/ml) were each diluted in 24 µl OPTI-MEM reduced 
serum medium (Gibco) and pooled afterwards. In all experiments 0.2 µg of a renilla 
luciferase construct (1 mg/ml) were cotransfected to normalize expression. The 
solution was incubated at room temperature for 15 min. Meanwhile, medium was 
removed from the 24-well plate and 250 µl DMEM + glutamine without FCS and 
antibiotics was added. After the 15 min incubation, the 50 µl of the solution were added 
to the 250 µl medium and MEFs were transfected for 3 h. Afterwards, the supernatant 
was removed and DMEM + glutamine + Pen/Strep + 10 %FCS was added over night. 
The next day, cells were pretreated as indicated and then stimulated for 24 h. After 
stimulation, cells were washed twice in PBS and taken up in 100 µl /well 1x Passive 
Lysis Buffer (Promega). The plate was shaken for 30 min at room temperature and 
then a luciferase assay (Promega Dual-Luciferase Reporter Assay System) was 
performed. For this, 10 µl of the cell lysate were transferred into a luminometer tube. 
The tube was inserted into the luminometer (Lumat LB9507, Berthold Biotechnologies) 
and the measurement was performed automatically by the instrument. First, the firefly 
luciferase activity was measured by the addition of LARII buffer. Through the addition 
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of the Stop/Glo buffer, the activity of the firefly luciferase was inhibited, while the renilla 
luciferase was activated. After measuring the activity of the renilla luciferase, the ratio 
between the activities of the firefly and the renilla luciferase was calculated by the 
luminometer. 
3.2.13 Luminex 
In order to determine cytokine levels, cell-free supernatants were taken off and 
stored at -20°C until analyzed by Luminex. The assays were performed by Margarethe 
Merio. Human cytokine levels were determined using following antibodies: IL-12p40, 
IL-12p70, IL-10, TNF-α, IL-6, IFN-γ, IL-1β and IL-17 (all R&D Systems). Mouse 
cytokine levels were measured by the use of the 6-plex Procarta Cytokine Assay Kit 
(Affymetrix) with antibodies to IL-12p40, IL-12p70, IL-10, TNF-α, IL-1β and IL-23. 
3.2.14 Annexin V staining 
3x105 monocytes were seeded on a 24-well plate and pretreated as indicated. After 
24 h stimulation with LPS, the cells were transferred to a FACS-tube and washed twice 
with PBS. Cells were resuspended in 300 µl of 1x Annexin V Binding Buffer and 100 µl 
of the solution were transferred to a new FACS-tube. Cells were incubated for 15 min 
with 5 µl FITC-labelled Annexin V (Alexis) and 5 µl propidium iodid (Sigma) in the dark. 
Afterwards, 400 µl of 1x Annexin V Binding Buffer were added and cells were analyzed 
within one hour on a FACSCanto II (BD Bioscience). 
3.2.15 Homogenisation of mouse tissue 
Homogenisation of mouse tissue was performed by using the Precellys-ceramic kit 
2.8 mm and the Precellys 24 tissue homogenizer (both from peQLab). Mouse tissue 
was dissected on dry ice and 30 mg were transferred to a 2 ml tube containing the 
beads. All the steps were performed without allowing the tissue to thaw. Afterwards,  
1 ml Tx-100 Lysis Buffer was added and the tube was placed into the homogenizer. 
After the program (2x15 sec) was finished, the samples were incubated on ice for  
30 min and centrifuged for 10 min at 4°C and 16000 g to pellet cell debris. Supernatant 
was transferred to a new tube and Western Blot samples were prepared as described 
earlier. 
In order to isolate RNA from mouse tissue, 1 ml TRIzol instead of 1 ml Tx-100 Lysis 
Buffer was added and the same program as described above was performed on the 
tissue homogenizer. After the program was finished, we stored the samples at -20°C 
until isolating RNA as described earlier. 
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3.2.16 Listeria monocytogenes mouse model 
Dr. Caroline Lassnig from the University of Veterinary Medicine Vienna performed 
the in vivo experiments. SB203580 hydrochloride (Cayman) was dissolved at 30 mg/ml 
in DMSO and further diluted to 1.5 mg/ml or 150 µg/ml with PBS for injection. Male 
C57BL/6 mice (10 weeks) were injected intraperitoneal with 30 µg/mouse SB203580 
hydrochloride or solvent controls. 30 min later, mice were injected with 5x106 Listeria 
monocytogenes EGD in PBS. Survival of the mice was monitored. 
In a different experiment, mice were pretreated as indicated and injected with  
5x106 Listeria monocytogenes in PBS. After 6 h, mice were anesthetized and blood 
samples were taken for determining cytokine levels. Spleens were also isolated and 
homogenized as described. 
3.2.17 p38α KO mice experiments 
The experiments were carried out at the Cutaneous Biology Research Center, 
Charlestown, Massachusetts (group of Jin Mo Park). The mice were on a C57BL/6 
background. 
For a restimulation experiment, three p38α fl/fl mice and three p38α fl/fl mice 
expressing Cre under the control of LysM, were injected with 25 µg/mouse LPS and 
splenocytes were harvested 48 h later. 5x105 splenocytes/well were restimulated with 
100 ng/ml LPS or solvent control. After 48 h, supernatants were taken off and frozen. 
For the isolation of organs, three p38α fl/fl mice and three p38α fl/fl mice expressing 
Cre under the control of LysM, were injected with 30 µg/mouse LPS. After 4 h, lungs 
and spleens from the mice were isolated and snap-frozen in 1.5 ml tubes. Sera 
samples were also taken from these mice. 
The material was sent to us and we performed Luminex and tissue homogenization 
as described. 
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4 Results 
4.1 Initial experiments 
4.1.1 p38 subunit expression in human CD14+ monocytes 
The p38 MAPK consists of the four subunits α, β, γ and δ. By measuring the mRNA 
and protein levels of the four subunits, Hale et al showed that p38α is the predominant 
form of p38 in human monocytes, followed by p38δ, whereas the expression of the 
p38β and γ subunits in monocytes is extremely low [65]. 
In order to extend these results and to investigate the effect of TLR stimulation on 
the expression of p38, we stimulated human monocytes with LPS and detected the 
expression of the subunits after 0, 1, 6 and 24 h by immunoblot. p38α was the 
dominant subunit expressed in human monocytes and its expression was not 
modulated by LPS stimulation. The second-highest expression levels were measured 
for p38δ. Again, there was no difference in the expression levels after TLR4 
stimulation. Interestingly, p38β was induced following treatment with LPS after 1 h, and 
decreased again after 6 and 24 h (Figure 5). As Hale et al could not detect any p38γ in 
human monocytes and we had no antibody available, we did not measure p38γ levels. 
In summary, we showed that p38α is the predominant p38 subunit expressed in human 
monocytes, followed by p38δ, whereas p38β is induced after stimulation with LPS in a 
time-dependent manner. 
LPS (h)
p38beta
p38delta
p38
p38alpha
0      1     6     24
Histon H3
0     1       6     24  
long exposure short exposure
 
Figure 5. p38 subunit expression in human monocytes 
Human CD14+ monocytes were stimulated with 100 ng/ml LPS for the indicated times. Whole-
cell lysates were analyzed by immunoblot. Representative blots for two independent 
experiments are shown. 
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4.1.2 Rapamycin and p38 inhibitors do not evoke cell death 
As it was important to know if the used inhibitors have an influence on cell viability, 
we performed Annexin V staining. The assay is based on the recognition of 
phosphatidylserine through Annexin V. Phosphatidylserine is normally distributed on 
the inner side of the cell membrane but translocates to the outer side when a cell 
undergoes apoptosis. The translocation also occurs during necrosis, with the difference 
that the cell wall becomes leaky during necrosis [66]. 
Human monocytes were pretreated as indicated and stimulated with LPS for 24 h. 
Afterwards, cells were stained with Annexin V and propidium iodide. Annexin V-positive 
cells were defined as being in early apoptosis, double-positive cells as being in late 
apoptosis or necrosis and double-negative cells as being living cells. Figure 6 shows 
that there was nearly no difference in the cell viability comparing the different 
pretreated monocytes. The highest number of apoptotic and necrotic cells was found in 
the unstimulated sample with less than 5 %. 
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Figure 6. Influence of the used reagents on cell viability 
Human monocytes were pretreated with medium, BIRB0796 (200 nm), SB203580 (2 µM) or 
rapamycin (100 nM) for 90 min and stimulated with LPS (100 ng/ml) for 20 h. Afterwards, cells 
were stained with Annexin V and propidium iodid. Annexin V-positive cells are defined as being 
in early apoptosis, double-positive cells as being in late apoptosis or necrosis and double-
negative cells as being living cells. 
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4.2 p38 regulates the production of IL-12p40 and IL-10 
4.2.1 p38 inhibition augments IL-12p40 and attenuates IL-10 cytokine levels 
Next, we investigated the modulation of the innate immune response after p38 
inhibition and TLR activation. Therefore, we pretreated freshly isolated human 
monocytes with the p38 inhibitors SB203580 or BIRB0796 and activated the cells with 
the TLR ligands LPS, Staphylococcus aureus (SAC), zymosan or Listeria 
monocytogenes. After stimulation for 24 h, we collected supernatants and determined 
cytokine levels. In order to compare the effects of p38 inhibition on cytokine production 
with the effects of mTOR inhibition, rapamycin was also used to manipulate the 
monocytes. 
Inhibition of p38 with different concentrations of SB203580 or BIRB0796 led to an 
increase in the IL-12p40 levels after stimulation with LPS, while the IL-10 levels were 
attenuated compared to LPS stimulation alone (Figure 7A). The production of TNF-α 
was abrogated after inhibition of p38, which was already described earlier [25]. 
Pretreatment with rapamycin similarly decreased the production of IL-10 but promoted 
the production of IL-12p40. The expression of TNF-α was not significantly altered 
compared to the stimulated control (Figure 7A). 
Inhibition of p38 followed by stimulation with the TLR2 ligand SAC and with Listeria 
monocytogenes (Figure 7B and 7E) showed similar results as the activation with LPS. 
Again, IL-12p40 levels raised and IL-10 levels decreased after pretreatment with 
BIRB0796 and rapamycin. As exception, inhibition of p38 with SB203580 did not 
augment IL-12p40, although IL-10 was still attenuated. In addition, the TNF-α levels 
were diminished after p38 inhibition, but did not change after rapamycin treatment. 
Figures 7C and 7D show the cytokine levels after activation of the monocytes with 
two different concentrations of zymosan, another known ligand of the TLR2. 
Pretreatment of the monocytes with rapamycin promoted IL-12p40 production and 
inhibited IL-10, while the TNF-α production was not influenced. However, inhibition of 
p38 and stimulation of the cells with zymosan, which has been shown to activate p38 in 
peritoneal mouse macrophages [67], did not show a significant alteration in the  
IL-12p40, IL-10 and TNF-α production (Figure 7C and 7D). In all of these experiments, 
we also measured the IL-6 levels, but there was no significant alteration with p38 or 
mTOR inhibition (data not shown). 
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Figure 7. p38 regulates IL-12p40, IL-10 and TNF-α production after TLR stimulation 
Human CD14+ monocytes were preincubated with medium, BIRB0796 (200 or 100 nM), 
SB203580 (2 µM or 200 nM) or rapamycin (100 nM) for 90 min and stimulated with either  
(A) LPS (100 ng/ml), (B) SAC (75 µg/ml), (C, D) zymosan (50 µg/ml or 100 µg/ml) or (E) Listeria 
monocytogenes (L.m.; 107 pfu/ml) for 20 h. IL-12p40, IL-10 and TNF-α in cell-free supernatants 
were measured by Luminex. Data represent the means ± SE of at least 3 donors. 
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Figure 8. p38 regulates IL-12p70 and IL-1β production after TLR stimulation 
Human CD14+ monocytes were preincubated with medium, BIRB0796 (200 or 100 nM), 
SB203580 (2 µM or 200 nM) or rapamycin (100 nM) for 90 min and stimulated with LPS  
(100 ng/ml) for 5 h or 20 h. For the measurement of (A) IL-12p70 production, cells were 
additionally stimulated with IFN-γ (30 ng/ml). For the measurement of (B) IL-1β, cells were 
additionally stimulated with 5 mM ATP for the final 45 min. Cytokine levels were determined by 
Luminex. IL-12p70 production is shown as the mean ± SE for at least 3 donors. IL-1β 
production is shown for two independent donors. 
In a next step, we were interested if p38 also modulates the production of the 
inflammatory cytokines IL-1β and the biologically active heterodimer IL-12p70, which is 
composed of the subunits IL-12p40 and IL-12p35. In order to stimulate the production 
of IL-12p70 from human monocytes, we stimulated them with LPS in combination with 
IFN-γ. Similar to mTOR inhibition, inhibition of p38 increased the levels of IL-12p70 
(Figure 8A). To gain insight into potential alterations of IL-1β production after p38 
inhibition, cells were pretreated as described and activated with LPS in combination 
with ATP. The results for the two donors are quite different. While donor 1 showed 
impaired levels of IL-1β after p38 inhibition and TLR4 activation, donor 2 showed no 
alterations after treatment with BIRB0796 but higher levels of IL-1β after pretreatment 
with SB203580 (Figure 8B). Pretreatment with rapamycin and stimulation with LPS for 
24 h had no influence on the production of IL-1β, while stimulation with LPS for 5 h 
diminished the levels of IL-1β. 
Summarized, we show that inhibition of p38, similar to inhibition of mTOR, leads to a 
proinflammatory phenotype after activation with TLR ligands characterized by higher 
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levels of the proinflammatory IL-12p40 and lower levels of the anti-inflammatory IL-10. 
The production of the bioactive IL-12p70 heterodimer is also boosted after inhibition of 
p38 and activation with the TLR4 ligand LPS. 
4.2.2 Different regulation of IL-12p40 and IL-10 in moDCs and mDCs 
It was recently shown in our laboratory that mTOR plays a divergent role in mDCs 
and moDCs [68]. In mDCs, inhibition of mTOR increases proinflammatory cytokines 
and decreases the levels of IL-10 after TLR activation, while in moDCs this 
immunostimulatory phenotype is blocked [68]. We were now interested if inhibition of 
p38 shows similar effects as inhibition of mTOR in mDCs and moDCs. 
moDCs and mDCs were generated as described, pretreated with p38 or mTOR 
inhibitors and stimulated with different TLR ligands. In moDCs, inhibition of p38 blocked 
IL-10 and IL-12p40 production after stimulation with LPS. Inhibition of mTOR with 
rapamycin also decreased the levels of IL-10, while there was no influence on the  
IL-12p40 production. TNF-α production did not change after inhibition of p38 or mTOR. 
Stimulation of moDCs with SAC did hardly lead to any IL-10 production and the levels 
did not change after blocking p38 or mTOR. IL-12 production was diminished after 
inhibition of p38 but enhanced after inhibition of mTOR (Figure 9A). 
In mDCs, IL-10 was blocked after inhibition of p38 or mTOR and activation with the 
TLR ligands LPS, SAC or Listeria monocytogenes. The levels of IL-12p40 were 
augmented after pretreatment with p38 and mTOR inhibitors. TNF-α levels were 
unaltered after treatment with rapamycin, while they were diminished or also unaltered 
after inhibition of p38 (Figure 9B). 
In summary, we extend our previous results with mTOR inhibitors and additionally 
show that inhibition of p38 differently regulates cytokine production in moDCs and 
mDCs. 
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Figure 9. Different regulation of IL-12p40 and IL-10 levels in moDCs and mDCs 
(A) Human moDCs or (B) mDCs were generated as described, preincubated with medium, 
BIRB0796 (200 nM), SB203580 (2 µM) or rapamycin (100 nM) for 90 min and stimulated with 
LPS (100 ng/ml), SAC (75 µg/ml) or Listeria monocytogenes (107 pfu/ml) for 20 h. IL-12p40,  
IL-10 and TNF-α levels in cell-free supernatants were assessed by Luminex. Cytokine levels of 
moDCs are shown as means ± SE for 3 donors. Cytokine levels of mDCs are shown for two 
independent donors. 
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4.2.3 p38 regulates IL-12p40 and IL-10 mRNA levels 
The results so far indicate that blocking of p38 increases the protein levels of  
IL-12p40, while it decreases the levels of IL-10 after TLR stimulation. In order to 
investigate whether the production of these cytokines is regulated on the transcriptional 
level, we measured the mRNA levels at different time points of LPS stimulation. Figure 
10 illustrates that the IL-12p40mRNA levels were augmented after pretreatment with 
BIRB0796, SB203580 or rapamycin, while the IL-10 levels were reduced. However, the 
mRNA levels of IL-23p19, which together with IL-12p40 forms the active IL-23, were 
diminished after p38 inhibition. After inhibition of mTOR, the mRNA levels of IL-23p19 
increased (Figure 10). 
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Figure 10. p38 regulates IL-12p40 and IL-10 mRNA production 
Human CD14+ monocytes were preincubated with medium, BIRB0796 (200 nM), SB203580  
(2 µM) or rapamycin (100 nM) for 90 min and stimulated with LPS (100 ng/ml) for 2, 4 or 6 h.  
IL-12p40, IL-10 and IL-23 mRNA levels were determined by RT-PCR. mRNA levels were 
normalized to ubiquitin and are shown as fold increases over the unstimulated controls. 
Representatives for two independent experiments are shown. 
To further demonstrate the functional relevance of p38 for IL-12 production, we 
hyperactivated p38 with anisomycin or UV in the presence of LPS. Costimulation with 
LPS and UV diminished IL-12p40 levels (Figure 11A). Moreover, IL-12p40mRNA levels 
were strongly reduced when stimulating with LPS and UV or LPS and anisomycin 
simultaneously (Figure 11B). 
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Figure 11. Hyperactivation of p38 diminishes IL-12p40 
(A) Human monocytes were activated with LPS (100 ng/ml) and/or UV (as described in 
materials and methods) for 20 h. IL-12p40 levels in cell-free supernatants were determined by 
Luminex. Data of two different donors are shown. (B) Human monocytes were activated with 
different combinations of LPS (100 ng/ml), anisomycin (50 ng/ml) and UV for 2 h. IL-12p40 
mRNA levels were measured by RT-PCR and normalized to ubiquitin. Fold increases over 
unstimulated controls are illustrated. Data of two independent donors are shown. 
Sp1 (Specificity protein 1) has been shown to be a transcription factor important for 
the regulation of IL-12p40. Therefore, we determined the influence of mithramycin, a 
known inhibitor of Sp1, on IL-12p40 production. Pretreatment with mithramycin 
decreased the levels of IL-12p40 after LPS stimulation (Figure 12A). Importantly, the 
augmented production of IL-12p40 after BIRB0796 or rapamycin pretreatment could be 
reversed by concomitant treatment with 100 nM or 300 nM mithramycin (Figure 12A). 
These results suggest that inhibition of mTOR and p38 might enhance Sp1 activity to 
promote IL-12p40 production, which can be inhibited by the Sp1 inhibitor mithramycin. 
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Figure 12. Possible role for Sp1 in regulating IL-12p40 production 
(A) Human CD14+ monocytes were preincubated with medium, BIRB0796 (200 nM), rapamycin 
(100 nM) and/or mithramycin (100 nM or 300 nM) for 90 min and stimulated with LPS  
(100 ng/ml) for 24 h. IL-12p40 cytokine levels in cell-free supernatants were determined by 
Luminex. Data are shown as means ± SE for two donors. (B) TSC2+/+ and TSC2-/- MEFs were 
transfected with an Sp1-Luc plasmid as described. After transfection, cells were pretreated with 
medium, BIRB0796 (200 nM) or rapamycin (100 nM) and stimulated with anisomycin  
(100 ng/ml) for 24 h. Luciferase assay was performed as described. The ratio from the Sp1-
fireflly luciferase activity to renilla luciferase activity is shown. The experiment was performed in 
duplicates. 
Moreover, transfection of an Sp1-plasmid into TSC2+/+ and TSC2-/- MEFs revealed 
that the activity of Sp1 was higher in TSC2+/+ MEFs compared to the TSC2-/- MEFs, 
suggesting that activation of mTOR inhibits Sp1 activity. In line, stimulation of p38 with 
anisomycin reduced the activity of Sp1 in TSC2+/+ MEFs compared to the 
unstimulated control. Pretreatment with BIRB0796 or rapamycin of anisomycin-
stimulated TSC2+/+ cells restored the activity of Sp1 compared to anisomycin alone. 
Furthermore, stimulation with anisomycin blocked the activity of Sp1 in TSC2-/- MEFs, 
however, BIRB0796 failed to enhance the activity of Sp1 in these cells (Figure 12B). 
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These results indicate that activation of p38 via TSC2 and mTOR may reduce Sp1 
activity, which is critical for IL-12p40 production. 
4.3 A novel link from p38 to mTOR 
4.3.1 Inhibition of p38 blocks mTOR 
To analyze the molecular mechanisms of how the p38 and mTOR signaling might 
interact, we investigated if p38 is able to modulate mTOR signaling. Therefore, we 
pretreated human monocytes with different p38 inhibitors or rapamycin and stimulated 
them with LPS, anisomycin or UV, known activators of p38. We confirmed blocked p38 
signaling by analyzing the phosphorylation status of MK2, a substrate of p38. While the 
inhibitors BIRB0796 and SB203580 blocked the phosphorylation of MK-2 after 
activation with LPS, SD-169 did not (Figure 13A). These results indicate that SD-169 
does not block p38 activation in human monocytes in vitro. Strikingly, inhibition of p38 
with BIRB0796 and SB203580 was able to block mTOR signaling after stimulation with 
LPS, anisomycin or UV. This was shown by the reduced phosphorylation of S6 and  
4E-BP1 (Figures 13A, B, C). Additionally, the phosphorylation of p-p70S6K, a direct 
mTORC1 substrate and the kinase that phosphorylates p-S6, was totally blocked after 
treatment with BIRB0796 and SB203580 in LPS-stimulated monocytes (Figure 13A). 
As expected, the mTOR inhibitor rapamycin inhibited the phosphorylation of p70S6K, 
S6 and 4E-BP1. Moreover, the phosphorylation status of p38 was not affected by 
rapamycin (Figures 13A, B, C). p38 inhibition also led to an enhancement in the 
phosphorylation of ERK and c-jun, while rapamycin did not affect them. Interestingly, 
phosphorylation of Akt at Ser473 was blocked with the p38 inhibitors BIRB0796 and 
SB203580, while it was not blocked after pretreatment with rapamycin. The 
phosphorylation of GSK3 was not affected by p38 or mTOR inhibition (Figures 13A, C). 
Compared to the unstimulated control, the phosphorylation status of IκB-α was 
diminished with LPS stimulation, but there was no further modulation after pretreatment 
with p38 inhibitors or rapamycin (Figure 13A). 
In conclusion, we demonstrate that inhibition of p38 strongly reduces mTOR 
signaling after stimulation with TLR-dependent and –independent stimuli indicating that 
p38 is a bona-fide activator of mTORC1 signaling. 
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Figure 13. Inhibition of p38 blocks mTOR 
Human monocytes were preincubated with medium, BIRB0796 (200 nM), SB203580 (2 µM), 
SD169 (200 nM) or rapamycin (100 nM) for 90 min and stimulated with (A) LPS (100 ng/ml),  
(B) anisomycin (50 ng/ml) or (C) UV (as described in methods) for the indicated times. Whole-
cell lysates were analyzed by immunoblot. Representatives of at least two independent 
experiments are shown. 
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As the p38MAPK consists of four different subunits (α, β, γ and δ), we wanted to 
know which of these subunits might be responsible for the activation of mTOR. The 
concentrations of the inhibitors used so far were in a range where they blocked 
specifically p38α and p38β and we also knew that the expression of p38β is very low in 
monocytes. Therefore, we made use of p38α fl/fl and p38α fl/fl LysMCre ∆p38α bone 
marrow derived mouse macrophages to test the effect of p38α knockout on mTOR and 
on cytokine expression. On the molecular level, p38α was expressed in the p38α fl/fl, 
but not in the p38α fl/fl LysMCre ∆p38α macrophages (Figures 14A, B). Interestingly, 
stimulation with LPS, anisomycin, UV or Listeria monocytogenes induced a strong 
phosphorylation of S6 in the p38α fl/fl macrophages, while the phosphorylation was 
blocked in the p38α fl/fl LysMCre ∆p38α macrophages (Figure 14A, B). Stimulation 
with Listeria monocytogenes also activated 4EBP1 and p70S6K in the p38α fl/fl 
macrophages but failed to do so in the p38α fl/fl LysMCre ∆p38α macrophages (Figure 
14B). These results extend the findings in human cells and demonstrate that p38α 
activates mTORC1 in response to LPS, or stress-induced signals such as UV or 
anisomycin. 
Next, we wanted to assess the functional importance of p38α in the bone marrow 
macrophages. The levels of IL-10 were attenuated in the p38α fl/fl LysMCre ∆p38α 
macrophages, compared to the p38α fl/fl macrophages, after stimulation with LPS, 
SAC or Listeria monocytogenes, respectively. Moreover, the production of IL-12p40 
and IL-12p70 was augmented in the p38α knockout macrophages after treatment with 
LPS or SAC, while there was no significant increase in the Listeria monocytogenes-
treated knockout macrophages. The levels of IL-1β, IL-23 and TNF-α were not altered 
when comparing the p38α fl/f and p38α fl/fl LysMCre ∆p38α macrophages after 
stimulation with LPS, SAC or Listeria monocytogenes (Figure 14C), demonstrating that 
p38α is a major regulator of the Il12/IL10 axis in murine macrophages. 
  
40
 
0
20
40
60
80
100
- LPS SAC L.m.
IL
-1
be
ta
 [p
g/
m
l]
0
100
200
300
400
500
- LPS SAC L.m.
IL
-1
0 
[p
g/
m
l]
0
2000
4000
6000
8000
10000
12000
14000
- LPS SAC L.m.
IL
-1
2p
40
 [p
g/
m
l]
0
5
10
15
20
- LPS SAC L.m.
IL
-2
3 
[p
g/
m
l]
0
500
1000
1500
2000
2500
- LPS SAC L.m.
TN
Fa
lp
ha
 [p
g/
m
l]
p38α fl/fl
p38α fl/fl LysMCre ∆p38α
0
100
200
300
400
- LPS SAC L.m.
IL
-1
2p
70
 [p
g/
m
l]
LPS
UV
Aniso
-
-
-
+
-
-
-
+
-
-
-
+
-
-
-
+
-
-
-
+
-
-
-
+
GAPDH
p-S6
p38alpha
p-MK2
A B
+
-
-
+
-
+
+
-
L.m. 10^6
L.m. 10^7
p38alpha
p-p70S6
p-S6
p-4EBP1
GAPDH
1 21 2
C
 
Figure 14. The subunit p38α activates mTOR 
(A, B) p38α fl/fl (1) and p38α fl/fl LysMCre∆p38α (2) mouse macrophages were starved 
overnight and stimulated with medium, LPS (100 ng/ml), anisomycin (100 ng/ml) or UV (as 
described in materials and methods) for 1h, or with either 106 pfu/ml or 107 pfu/ml Listeria 
monocytogenes. Whole-cell lysates were analyzed by immunoblot. Representatives of two 
independent experiments are shown. (C) p38α fl/fl and p38α fl/fl LysMCre∆p38α mouse 
macrophages were starved overnight and stimulated with medium, LPS (100 ng/ml), SAC  
(75 µg/ml) or Listeria monocytogenes (107 pfu/ml) for 20 h. Afterwards, cytokine levels in the 
supernatants were determined by Luminex. Values are shown as means ± SE for two mice. 
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4.3.2 mTOR is activated via PI3K and p38 independently 
Having established that p38α is a bona-fide activator of mTORC1, we wanted to 
further dissect the molecular signaling of p38 to mTOR. Therefore, we were now 
interested if p38 mediates its effect on mTOR signaling via the canonical PI3K 
pathway. Therefore, we treated human monocytes with the PI3K inhibitor wortmannin 
and/or the p38 inhibitor BIRB0796 and stimulated them afterwards with either LPS or 
anisomycin. Treatment with wortmannin alone did not affect the phosphorylation status 
of p38 and MK-2 after stimulation with LPS or anisomycin (Figures 15A, B). Both 
inhibitors were able to block phosphorylation of S6 partially (Figures 15A, B). Notably, 
simultaneous blockade of PI3K and p38 completely blocked the phosphorylation of S6 
(Figures 15A, B). These results suggest that p38 is not downstream of PI3K, but serves 
as a second and parallel input signal to stimulate mTORC1 activity in human 
monocytes. 
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Figure 15. mTOR is activated via PI3K and p38 independently 
Human monocytes were preincubated with medium, BIRB0796 (200 nM) and/or wortmannin 
(100 nM) for 90 min and stimulated with (A) LPS (100 ng/ml) or (B) anisomycin (50 ng/ml) for 
the indicated times. Whole-cell lysates were analyzed by immunoblot. Representatives for two 
independent experiments are shown. 
In order to verify this dual input pathway for mTORC1 activation, we made use of 
the p38α fl/fl and p38α fl/fl LysMCre ∆p38α bone marrow-derived mouse macrophages. 
As expected, in the p38α fl/fl LysMCre ∆p38α macrophages, the p38 substrate MK-2 
was not activated after stimulation with LPS (Figure 16A). In addition, the 
phosphorylation of MK-2 was blocked in the p38α fl/fl cells after pretreatment with 
SB203580 (Figure 16A). Nevertheless, wortmannin did not affect MK2 phosphorylation 
after stimulation with LPS (Figure 16A). The phosphorylation of p70S6K and S6 was 
reduced after pretreatment with wortmannin or SB203580 and stimulation with LPS in 
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the p38 fl/fl macrophages. Moreover, the phosphorylation of these two proteins was 
even more reduced after simultaneous usage of SB203580 and wortmannin, indicating 
that p38 and PI3K are two independent signal inputs for mTOR activation also in 
mouse macrophages. In support, the activation of S6 and p70S6K was attenuated in 
the p38α fl/fl LysMCre ∆p38α macrophages compared to the p38α fl/fl macrophages 
and, as expected, SB203580 only modestly affected the phosphorylation of p70S6K 
and S6 in the p38 knockout macrophages, while the use of wortmannin could further 
block S6 and p70S6K. Concomitant treatment with SB203580 and wortmannin in the 
p38α fl/fl LysMCre ∆p38α macrophages totally abrogated the phosphorylation of S6 
and p70S6K (Figure 16A). Similar results were obtained when anisomycin was used to 
activate p38 and mTORC1 and BIRB0796 to inhibit p38 (Figure 16B). 
To further confirm these results, we analyzed single cells by immunocytochemistry. 
Stimulation of p38α fl/fl macrophages with LPS activated S6, while this activation was 
attenuated in the p38α fl/fl LysMCre ∆p38α macrophages. Moreover, inhibition of PI3K 
in the p38α fl/fl blocked phosphorylation of S6. Strikingly, inhibition of PI3K in the p38α 
fl/fl LysMCre ∆p38α macrophages completely blocked S6 phosphorylation (Figure 
17A). MK-2 was activated after treatment with LPS and pretreatment with wortmannin 
did not alter the activation status of this protein in the p38α fl/fl macrophages, whereas 
the phosphorylation of MK2 was inhibited in the p38α knockout macrophages (Figure 
17B). These results establish that p38α activates mTOR signaling cooperatively with 
PI3K. 
 
  
43
 
p-S6
p38alpha
p-MK2
p-p70S6
S6
4EBP1
GAPDH
A
p38alpha
p-p70S6
p-S6
p-4EBP1
GAPDH
Aniso
BIRB
Wortmannin
-
-
-
+
-
-
+
+
-
+
-
+
-
-
-
+
-
-
+
+
-
+
+
+
+
+
+
+
-
+
p38α fl/fl p38 α fl/fl
LysMCre ∆p38 α
B
LPS
SB203580
Wortmannin
-
-
-
+
-
-
+
+
-
+
-
+
-
-
-
+
-
-
+
+
-
+
+
+
+
+
+
+
-
+
p38α fl/fl p38 α fl/fl
LysMCre ∆p38 α
 
Figure 16. PI3K inhibition in p38α knockout macrophages completely blocks mTOR 
p38α fl/fl and p38α fl/fl LysMCre∆p38α mouse macrophages were starved over night and 
pretreated with medium, BIRB0796 (200 nM), SB203580 (2 µM) and/or wortmannin (100 nM) 
for 90 min. Afterwards cells were stimulated with (A) LPS (100 ng/ml) or (B) anisomycin  
(100 ng/ml) for 1 h. Whole-cell lysates were analyzed by immunoblot. Representatives of two 
independent experiments are shown. 
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Figure 17. The subunit p38α and PI3K activate mTOR independently 
p38α fl/fl and p38α fl/fl LysMCre∆p38α mouse macrophages were starved over night and 
pretreated with medium or wortmannin (100 nM) for 90 min. After stimulation with LPS  
(100 ng/ml) for 1 h, intracellular signaling was analyzed by immunocytochemistry. Antibodies 
against (A) p-S6 and (B) p-MK-2 were used. Nuclei were stained by using Hoechst 33342. 
Representatives for two independent experiments are shown. 
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4.3.3 p38 activates mTOR via TSC2 
To further characterize the PI3K-indepdendent activation of mTOR by p38α, we 
made use of TSC2-/- murine embryonic fibroblasts (MEFs). TSC2 is in a complex with 
TSC1 and is a negative regulator of mTOR. After being phosphorylated by Akt, TSC2 
becomes inactive and can no longer inhibit mTOR leading to constitutive mTOR 
activation [69]. 
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Figure 18. p38 activates mTOR via TSC2 
TSC2+/+ p53-/- and TSC2-/- p53-/- MEFs were starved overnight and pretreated with medium, 
BIRB0796 (200 nM), SB203580 (2 µM) or rapamycin (100 nM) for 90 min. Afterwards, MEFs 
were stimulated with (A) anisomycin (100 ng/ml), (B) UV (as described in methods), (C) LPS 
(100 ng/ml) or (D) 10 % FCS for 60 min. Whole-cell lysates were analyzed by immunoblot. 
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When stimulating the TSC2+/+ and TSC2-/- MEFs with anisomycin or UV, the 
proteins p38, S6 and p70S6K were strongly activated (Figures 18A, B). Strikingly, the 
p38 inhibitors BIRB0796 and SB203580 were able to block the phosphorylation of S6 
and p70S6K in the TSC2+/+ MEFs, while they failed to do so in the TSC2-/- MEFs 
(Figures 18A, B). Rapamycin was able to inhibit the phosphorylation of the mTOR 
substrates, both in the TSC2+/+ and TSC2-/- MEFs (Figures 18A, B) suggesting that 
p38 activates mTOR signaling by TSC2. 
LPS is only a poor stimulator for MEFs. Hence, stimulation of TSC2+/+ MEFs with 
LPS did not activate p38 or mTOR (Figure 18C). Nevertheless, pretreatment with 
rapamycin blocked the phosphorylation of S6 and p70S6K (Figure 18C). The loss of 
TSC2 caused hyperactivation of mTOR, which could be blocked with rapamycin, but 
not with the p38 inhibitors (Figure 18C). 
Activation of the MEFs with 10 % FCS led to a strong phosphorylation of p70S6K 
and S6, while p38 was not phosphorylated (Figure 18D). Again, the phosphorylation of 
p70S6K and S6 could only be blocked with rapamycin in the TSC2+/+ and TSC2-/- 
MEFs, respectively (Figure 18D). Pretreatment with BIRB0796 and SB203580 did not 
alter the phosphorylation status of S6 or p70S6K after stimulation with 10 % FCS 
(Figure 18D) indicating that serum activates mTOR in a p38-independent way. 
In summary, LPS and 10 % FCS failed to activate p38 in the MEFs and therefore, 
p38 inhibitors had no effect on the phosphorylation status of the mTOR substrates. In 
contrast, stimulation with anisomycin and UV strongly activated p38. Inhibition with 
BIRB0796 and SB203580 blocked mTOR in the TSC2+/+ MEFs, but not in the TSC2-/- 
MEFs suggesting that p38 activates the mTOR pathway via TSC2. The lack of TSC2 
had no effect on the inhibitory function of rapamycin due to the fact that rapamycin 
inhibits mTOR downstream of TSC2. 
4.4 p38 inhibition induces Th1 response 
4.4.1 Inhibition of p38 upregulates CD86 on mDCs 
To investigate what consequences inhibition of p38 has on the development of an 
inflammatory immune response, we analyzed the regulation of CD86 (B7-2) on mDCs 
after treatment with p38 inhibitors. CD86 belongs together with CD80 (B7-1) to an 
important class of costimulators for T lymphocytes. These two molecules are 
expressed on macrophages, B lymphocytes and dendritic cells [1]. 
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Figure 19. Inhibition of p38 upregulates CD86 on human mDCs 
mDCs were generated as described and pretreated with medium, BIRB0796 (200 nM) or 
SB203580 (2 µM) for 90 min. Afterwards, cells were stimulated with (A) LPS (100 ng/ml),  
(B) Listeria monocytogenes (107 cfu/ml) or (C) SAC (75 µg/ml) for 24 h. Subsequently, mDCs 
were prepared for FACS analysis. Representatives for two independent experiments are shown. 
After treating mDCs with medium, BIRB0796 or SB203580 cells were stimulated 
with LPS, SAC or Listeria monocytogenes. After gating the mDCs, we generated a 
histogram for the CD86 positive cells (Figures 19A, B, C). Figure 19A shows that 
stimulation with LPS upregulates CD86 on mDCs compared to the unstimulated 
control. Moreover, CD86 expression is even higher after pretreatment with the p38 
inhibitors SB203580 and BIRB0796 (Figure 19A). The same results were achieved 
after stimulation with Listeria monocytogenes (Figure 19B) and SAC (Figure 19C). 
Thus, inhibition of p38 boosted the expression of CD86 on mDCs. 
4.4.2 p38 inhibition in monocytes promotes Th1 differentiation 
In order to investigate if inhibition of p38 or mTOR in monocytes can elicit different 
T-cell responses after LPS stimulation, we established a T-cell differentiation assay. 
Monocytes were isolated from whole blood as described and treated with medium, 
BIRB0796, SB203580 or rapamycin. After stimulation with LPS for 24 h, monocytes 
were washed and incubated with CD4+ T lymphocytes. 
After one week of priming, supernatants were taken off. Rapamycin, BIRB0796 and 
SB203580 pretreated monocytes induced elevated production of IFN-γ after LPS 
stimulation, compared to LPS stimulation without pretreatment (Figure 20A). The IL-17 
levels were not altered in the BIRB0796 and SB203580 treated monocytes, while they 
were reduced in the rapamycin treated cells (Figure 20A). 
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To further analyze a potential influence of p38 on T-cell differentiation, primed  
T-cells were activated for 5 h with PMA/Ionomycin. Figure 20B shows that there was 
nearly no IL-4 production after T-cell activation with PMA/Ionomycin. LPS-treated 
monocytes elicited an IFN-γ response in the CD4+ T-cells that was even higher in 
rapamycin, BIRB0796 and SB203580 pretreated monocytes (Figure 20B). These 
results indicate that the proinflammatory phenotype (high IL-12p40/ low IL-10), which 
was observed in the SB203580 and BIRB0796 treated monocytes, is able to promote 
Th1 responses. This is comparable with rapamycin-pretreated monocytes, which were 
also able to enhance Th1 responses. 
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Figure 20. p38 inhibition in monocytes promotes Th1 differentiation 
Human CD14+ monocytes were pretreated for 90 min with medium, BIRB0796 (200 nM), 
SB203580 (2 µM) or rapamycin (100 nM) and activated with LPS (100 ng/ml). After 20 h 
stimulation, allogeneic PBMCs were primed with those monocytes for one week. (A) IFN-γ and 
IL-17 levels in cell-free supernatants were determined by Luminex. Data represent means ± SE 
for at least three independent experiments. (B) Primed PBMCs were activated for 5 h with  
50 ng/ml PMA and 200 ng/ml Ionomycin in the presence of 10 µg/ml Brefeldin A for the last 3 h. 
Intracellular cytokine staining for IL-4 and IFN-γ in CD-4 T-cells is illustrated. Representatives 
for at least three independent experiments are shown. 
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4.5 In vivo experiments 
4.5.1 Macrophage specific p38α KO in mice alters mTOR pathway 
Next, we wanted to corroborate our findings in vivo and tested the effects of p38 
inhibition for cytokine production and activation of mTOR. Therefore, mice with a 
macrophage specific knockout of p38α were challenged with LPS. The IL-10 levels in 
the sera of p38α knockout mice were attenuated compared to the p38α fl/fl mice, while 
the levels of IL-12p40 and IL-12p70 were augmented (Figure 21A). However, the 
production of IL-23, TNF-α and IL-1β was not altered when comparing the p38α fl/f and 
p38α fl/fl LysMCre ∆p38α mice (Figure 21A). 
Moreover, reactivated splenocytes from p38α fl/fl LysMCre ∆p38α mice displayed 
higher levels of IL-12p40 in the supernatants compared to the splenocytes of p38α fl/fl 
mice. The TNF-α production was not altered (Figure 21B). Figure 21C shows that 
p70S6K and 4EBP1 were activated in spleens from p38α fl/fl mice challenged with 
LPS, while the phosphorylation of these proteins was totally blocked in p38α fl/fl 
LysMCre ∆p38α spleens. 
In summary, these results indicate that p38α is important for the activation of mTOR 
in macrophages in vivo and modulates IL-10/IL-12 signaling. 
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Figure 21. p38α knockout in mice alters the mTOR pathway 
Three p38α fl/fl and three p38α fl/fl LysMCre∆p38α were injected with 30 µg/mouse LPS for 4 h. 
(A) Serum samples were taken and cytokine levels were determined by cytokine assay kit.  
(C) Spleens were isolated, homogenized and analyzed by immunoblot. The mTOR activation for 
two p38α fl/fl (1) and two p38α fl/fl LysMCre∆p38α (2) mice is shown. (B) Three p38α fl/fl and 
three p38α fl/fl LysMCre∆p38α were injected with 25 µg/mouse LPS for 4 h. Splenocytes were 
isolated and restimulated with 100 ng/ml LPS or solvent control. Cytokine levels in the cell free 
supernatant were determined by cytokine assay kit. 
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4.5.2 p38 inhibition in C57BL/6 mice has no influence on Listeria infection 
Next, we wanted to find out whether inhibition of p38 with SB203580 displays the 
same inflammatory phenotype as the macrophage specific knockout of p38α in mice. 
Therefore, we made use of C57BL/6 mice and challenged them with Listeria 
monocytogenes. 
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Figure 22. p38 inhibition in C57BL/6 mice has no influence on Listeria infection 
(A) C57BL/6 mice were injected with solvent control, 30 µg/mouse SB203580 or PBS. 30 min 
later, mice were injected with 5x106 Listeria monocytogenes or left untreated for 6 h. Serum 
samples were taken and cytokine levels were determined by cytokine assay kit. Cytokine levels 
are shown as means ± SE for at least three mice. (B) Spleens were isolated, homogenized and 
analyzed by immunoblot. Data from three DMSO treated, three SB203580 treated and one PBS 
treated mice, are shown. (C) C57BL/6 mice were injected with solvent control (n=18) or  
30 µg/mouse SB203580 (n=19). 30 min later mice were injected with 5x106 Listeria 
monocytogenes and survival of the mice was monitored. Summary of three independent 
experiments is shown. 
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Figure 22A shows that there was no induction of IL-12p40 production after Listeria 
monocytogenes infection. Moreover, pretreatment with SB203580 did not alter the  
IL-12p40 levels in the sera of C57BL/6 mice compared to solvent control-treated mice 
after Listeria infection (Figure 22A). 
In order to find out whether mTOR was activated after Listeria monocytogenes 
infection, we homogenized the spleens of the mice and analyzed the cell signaling by 
immunoblot. Only one out of three mice that were pretreated with DMSO and infected 
with Listeria showed an induction of p-p38, p-4EBP1, p-S6 and p-p70S6K, compared to 
the PBS treated, uninfected mice. The other two mice, which were pretreated with 
DMSO, showed weak or no induction of these proteins compared to the uninfected 
mice. Pretreatment with SB203580 and infection with Listeria monocytogenes kept the 
phosphorylation status of p38, p70S6K, S6 and 4EBP1 at the level of the uninfected 
mice (Figure 22B). 
Figure 22C illustrates that pretreatment with 30 µg/mouse SB203580 had no 
influence on the survival rate of C57BL/6 mice after infection with 5x106 Listeria 
monocytogenes. Eighty percent of both, the solvent control and the SB203580-treated 
mice, were dead 96 hours after the Listeria infection. 
Summarized, these results indicate that, p38 is not activated after Listeria 
monocytogenes infection and hence, does not contribute to IL-12p40 production in 
C57BL/6 mice in vivo. 
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5 Discussion 
We show here that p38 in human monocytes negatively regulates IL-12 production, 
while it promotes IL-10 in myeloid innate immune cells after stimulation with different 
TLR ligands. The enhanced inflammatory response after p38 inhibition was manifested 
by the potential of these cells to strongly promote Th1 differentiation in CD4+ T-cells. 
Moreover, we provide evidence for a connection between the p38 and mTOR pathway 
that has not been shown so far in innate immune cells. The link of these two pathways 
seems to be at the level or upstream of TSC2, which is a negative regulator of mTOR. 
Moreover, we could also identify p38α to be the isoform responsible for the activation of 
mTOR and the potential to modulate IL-10/IL-12. These findings provide a basis for a 
better understanding of the signal transduction pathways that regulate innate immune 
response. 
 
In the first steps of the work, we confirmed the findings from Hale et al and showed 
that p38α is the predominant subunit expressed in human monocytes [65]. The finding 
that p38β is time-dependently induced 1 hour after stimulation with LPS was quite 
interesting. This could indicate that this subunit has a role during the first steps of an 
immune response either to enhance these responses, or it may serve as a negative 
regulator. While p38δ was expressed second strongest in monocytes, we did not 
measure the levels of p38γ, as Hale et al showed that it is not expressed in human 
monocytes [65]. However, as most of the literature points to a role of p38α in 
inflammation, we moved on using p38α and p38β specific inhibitors in our experiments. 
 
Next, we analyzed the cytokine levels expressed by monocytes after inhibition of 
p38 or mTOR and stimulation with different bacterial stimuli. We confirmed the already 
known fact that inhibition of p38 blocks TNF-α production, as TNF-α is translationally 
regulated via the p38 substrate MK2 and TTP [4, 14, 26]. We found that the levels of 
IL-12p40 and IL-12p70 were increased after inhibition of p38 and TLR stimulation in 
human monocytes. Recently, Boucher et al also found in murine macrophages that p38 
negatively regulates IL-12 [63]. The finding was in line with the known augmentation of 
IL-12p40 and IL-12p70 expression after mTOR inhibition. Furthermore, the expression 
of the anti-inflammatory IL-10 was blocked with rapamycin pretreatment, as well as 
with inhibition of p38 after stimulation with different TLR ligands. Thus, inhibition of p38 
or mTOR followed by TLR stimulation displayed similar alterations of the cytokine 
milieu, providing a first hint that the p38 and mTOR pathway might be linked. 
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Interestingly, cytokine levels were not altered after p38 inhibition and activation with 
zymosan. This might be due to lack of p38 activation with zymosan in human 
monocytes. 
 
Furthermore, we were interested in the regulation of the IL-12p40 levels after 
inhibition of p38 in mDCs and moDCs, as it was recently shown in our lab that there is 
a divergent role in the differentiation of mDCs and moDCs. In mDCs, inhibition of 
mTOR increased proinflammatory cytokines and decreased the levels of IL-10 after 
TLR activation, while in moDCs this immunostimulatory phenotype was blocked [68]. 
We extended these results and investigated the role of p38 in mDCs versus moDCs. 
While there was an increase in the levels of IL-12p40 after p38 inhibition in the mDCs, 
there was a decrease in moDCs. The levels of IL-10 were blocked in both, the mDCs 
and moDCs after p38 inhibition and TLR activation. 
 
The real-time PCR data pointed to a role for p38 in regulating the production of IL-10 
and IL-12p40 at the transcriptional level. Comparable with direct inhibition of mTOR, 
the IL-12p40mRNA levels increased after inhibition of p38, while the IL-10mRNA levels 
were impaired. In contrast, the mRNA levels of IL-23p19 were attenuated after 
inhibition of p38, while they were enhanced after direct inhibition of mTOR. Further 
investigation revealed that treatment with mithramycin, which is an inhibitor of Sp1, 
could block the enhanced cytokine production of IL-12p40 after p38 inhibition. 
Additionally, an Sp1-Luc plasmid that was transfected into MEFs, showed higher 
activity after inhibition of p38 or mTOR. These findings were in line with some recently 
published works and point to a role of Sp1 in the transcriptional regulation of IL-12p40 
after p38 or mTOR inhibition. Dobreva et al showed that a CTCTAA/GC polymorphism 
in the IL-12p40 gene (IL-12B) influences the effects of p38 inhibition on IL-12p40 
production in PBMCs [70]. Shimokawa et al found that this polymorphism affects the 
transcriptional activity of the IL-12p40 promoter, by showing that the transcriptional 
activity of the GC allele is higher than that of the CTCTAA allele. Moreover, the 
transcription factor Sp1 binds with high affinity to a region including the GC sequence, 
while it fails to bind a region including the CTCTAA sequence [71]. Furthermore, 
Boucher et al showed that the binding of Sp1 to the IL-12p40 promoter is enhanced 
after inhibition of p38 by SB203580 [63]. Interestingly, Astrinidis et al recently identified 
Sp1 to interact with p70S6K in fibroblasts. Cells deficient in Sp1 show strong S6 
phosphorylation indicating that Sp1 could be regulated via mTOR to regulate the 
transcription of IL-12p40 [72]. As there are several transcription factors involved in the 
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regulation of IL-12p40, further analysis, which is ongoing, will be required to more 
clearly understand the mechanisms of transcription factor activation and the 
relationship between them. As Sp1 seems to have an important role within the 
signaling of the mTORC1 substrates, it would be interesting to further dissect its role in 
signaling, the precise mechanisms of its activation and the associated function as a 
transcription factor for IL-12p40. 
 
Flow cytometry analysis revealed that CD86, an important costimulator for T 
lymphocytes, was upregulated on mDCs after p38 inhibition and stimulation with LPS, 
Listeria monocytogenes or SAC. Together with the finding that IL-12p40, which is 
important for the differentiation of Th1 cells, was augmented in monocytes after 
pretreatment with SB203580 or BIRB0796, this suggested that inhibition of p38 in 
monocytes might modulate the differentiation pattern of CD4+ T-cells. Indeed, our 
results showed that inhibition of p38 or mTOR in human monocytes promoted Th1 
differentiation. Recently, Yang et al showed that p38 inhibition in murine BMDM 
promotes Th1 differentiation [73]. 
 
Based on these findings, we wanted to gain insight into the molecular mechanisms 
of how p38 and mTOR signaling might be connected. As rapamycin treatment did not 
alter p38 phosphorylation after TLR activation, p38 was not downstream of mTOR. 
Most interestingly, p38 inhibition in human monocytes was able to block the substrates 
of mTOR after stimulation with LPS, anisomycin or UV, strongly suggesting that p38 
activates mTOR. Interestingly, inhibition of p38 or PI3K could only partially block the 
mTOR substrates, while direct inhibition of mTOR with rapamycin could totally block 
the phosphorylation of S6 and 4EBP1. Further analysis showed that PI3K inhibition had 
no effect on the activation of p38 and that concomitant inhibition of PI3K and p38 was 
able to block mTOR totally. This pointed to a dual input to activate mTOR, on the one 
hand via the canonical PI3K pathway and on the other hand via p38 (Figure 23). 
 
Subsequently, we made use of TSC2 knockout MEFs to elucidate if the link from 
p38 to mTOR is upstream or downstream of TSC2. Stimulation of the MEFs with UV or 
anisomycin revealed that inhibition of p38 blocked mTOR in the TSC2+/+ MEFs, but 
failed to do so in the TSC2-/- MEFs. Again, rapamycin blocked the phosphorylation of 
the mTOR substrates, both in the TSC2+/+ and TSC2-/- MEFs. Thus, it was obvious 
that the signal from p38 to mTOR is mediated via TSC2 in MEFs. Whether this is also 
true for innate immune cells, needs further investigation. We would recommend 
  
56
 
knockdown experiments using TSC2 siRNA and inhibition of p38 with the used 
inhibitors. Interestingly, stimulation of MEFs with serum or LPS failed to activate p38 
and therefore, the p38 inhibitors had no effect on the phosphorylation status of S6 and 
4EBP1. 
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TSC1 TSC2
Rheb
mTORC1
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IL-12IL-10
environmental stress
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Figure 23. mTORC1 is activated via PI3K and p38 independently 
On the one hand, mTORC1 is activated via the PI3K/Akt axis. Activation of Akt inhibits TSC2, a 
negative regulator of mTORC1. On the other hand, mTORC1 is activated by p38 promoted 
inactivation of TSC2. Whether p38 inhibits TSC2 directly or via a downstream substrate of p38 
is not clear yet. 
As there are four isoforms of p38, we wanted to know which of them is responsible 
for the activation of mTOR. As the p38 inhibitor concentrations used were in a range 
where they blocked specifically the subunits p38α and p38β, we investigated the role of 
p38α by using p38α knockout BMDM. Stimulation of the cells with LPS, anisomycin, 
UV and Listeria monocytogenes revealed that knockout of p38α resulted in inhibition of 
the mTOR substrates S6 and 4EBP1. Again, we could show that only treatment with 
wortmannin and therefore inhibiting the input signal via PI3K, could completely block 
mTOR signaling in the p38α knockout macrophages, compared to a partial inhibition in 
the p38α floxed macrophages. This was shown both by immunoblot and 
immunofluorescence. Again, this suggests that mTOR is activated via PI3K and p38 
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independently and that the subunit p38α is responsible for the activation of mTOR. 
Nevertheless, knocking down the other subunits of p38 in human monocytes could 
further reveal their function in mTOR activation in innate immune cells. On the 
functional level, knockout of p38α and stimulation with LPS or SAC increased the 
cytokine levels of IL-12p40 and IL-12p70, while the levels of IL-10 were abrogated. 
This enhancement in IL-12p40 production was also shown by Kim et al in 2008 after 
stimulation of p38α knockout BMDM with LPS [74]. Although in our experiments, 
mTOR was blocked in the p38α knockout macrophages after stimulation with Listeria 
monocytogenes, the levels of IL-12p40 were not altered. This could be due to different 
downstream mediators that are activated or blocked by Listeria monocytogenes, but 
not by LPS or SAC. 
 
In order to investigate a link from p38 to mTOR in vivo, two different mouse models 
were used. Firstly, the immune response of p38α fl/fl LysMCre∆p38α mice after an LPS 
shock was analyzed. According to the results achieved in vitro, we found higher  
IL-12p40 serum levels in p38α fl/fl LysMCre∆p38α mice compared to the p38α fl/fl 
mice. Moreover, reactivated splenocytes of p38α fl/fl LysMCre∆p38α mice produced 
higher levels of IL-12p40, compared to the splenocytes of control mice. Immunoblot 
analysis of homogenized spleens revealed that mTOR was active in spleens of p38α 
fl/fl mice while it was blocked in spleens of p38α fl/fl LysMCre∆p38α mice. These in 
vivo results confirmed our observed findings, showing that p38α activates mTOR and 
that knockout of p38α leads to an inflammatory modulation of IL-12 and IL-10 after LPS 
shock. 
 
In contrast to these results, the immune response of C57BL/6 mice to a Listeria 
monocytogenes infection was not altered after treatment with 30 µg/mouse SB203580. 
Neither the IL-12p40 serum levels, nor the mTOR pathway was altered after 
pretreatment with the p38 inhibitor. Moreover, monitoring the survival revealed no 
differences in the survival rates of Listeria monocytogenes infected mice and mice 
infected with Listeria monocytogenes after pretreatment with the p38 inhibitor. 
Additionally, the phosphorylation status of p38 and the mTOR substrates in the spleens 
was not altered comparing uninfected and Listeria monocytogenes infected mice. The 
IL-12p40 serum levels also did not change after Listeria monocytogenes infection 
compared to the uninfected mice. This could mean that p38 was not activated in this in 
vivo model and therefore inhibition of p38 had no effect on the survival of the mice. It 
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could also be possible that Listeria monocytogenes blocked or enhanced downstream 
proteins that influence the IL-12p40 production. 
 
The primarily finding of our work was that p38 and the mTOR pathway are 
connected in innate immune cells. While I showed in this work that p38α enhances 
mTOR signaling in innate immune cells and MEFs, it was shown recently that p38β 
was involved in the suppression of mTORC1 in MEFs after energy starvation. This was 
mediated via activation of a pathway including PRAK (p38-regulated/activated kinase) 
and Rheb, which is a negative regulator of mTOR [75]. On the other hand, Li et al 
showed that MK2, a downstream substrate of p38, is responsible for the 
phosphorylation of TSC2 at Ser1210 in HEK293 cells. This phosphorylation enhanced 
the interaction of TSC2 with 14-3-3 and therefore led to an inhibition of TSC2 [76]. In 
Drosophila, p38 was shown to activate mTORC1 via an MK2 independent manner [77]. 
Further investigations will be required to reveal the exact function of the different p38 
subunits in activating mTOR in respect of different extra- and intracellular stimuli. The 
participation of the downstream substrates of p38 in p38/mTOR signaling could also be 
part of future investigations. 
 
Interestingly, some side findings came up when inhibiting p38 in human monocytes 
that could be possible targets for further investigations. One of these findings was that 
inhibition of p38 enhances the phosphorylation of ERK. Whether this is important in 
p38/mTOR signaling could be subject of further investigation, because increased ERK 
phosphorylation was also observed after p38 inhibition in a remnant kidney model. In 
this model, p38 inhibition was associated not with the expected improvement of renal 
disease, but with worsening [78]. In contrast, ERK was also found to phosphorylate and 
inactivate TSC2, thus activating mTOR [79]. In turn, this suggests that our observed 
downregulation of mTOR after p38 inhibition is not mediated via the activation of ERK. 
The Western Blot results also demonstrated that the phosphorylation of Akt at Ser473 
is inhibited after treatment with p38 inhibitors, while it is not inhibited with rapamycin. 
As there are three different isoforms of Akt in mammalian cells [42], further research is 
necessary to reveal which isoform is involved in mTOR signaling. How far mTORC2, 
which is known to phosphorylate Akt at Ser473, is involved in the p38/mTORC1 
signaling will also need further investigation. It would also be interesting to know if the 
signal is mediated directly from p38 to TSC2 or if it is transmitted via MK2, PRAK or 
MSK1/2 that are all substrates of p38. As already mentioned earlier, PRAK is involved 
in the inactivation of mTORC1 in energy-starved MEFs [75]. In contrast, MSK1/2 
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deficiency was shown to result in higher production of IL-12p40 and IL-12p70 [80]. 
Experiments with inhibitors of the downstream substrates or the use of knockout MEFs 
could reveal the importance of these substrates in our findings. 
 
In summary, our results display a role for p38 in limiting proinflammatory cytokine 
production after TLR-dependent and -independent stimulation that is mediated via the 
activation of mTOR. Inhibition of p38 in innate immune cells boosts the inflammatory 
reaction in vitro and in vivo. While activation of p38 in innate immune cells reduces the 
levels of IL-12p40, it enhances the levels of IL-10. This could be an important finding 
for new therapies of inflammatory diseases in respect of the balance of pro- and anti-
inflammatory cytokines. 
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